| 1 | Neuropathology meets chemical and genetic pathology head-on: a personal perspective | 1.6 | 1 | Citations (PDF) |
| 2 | The moderating effect of diet on the relationship between depressive symptoms and Alzheimer’s disease-related blood-based biomarkers | 3.4 | 0 | Citations (PDF) |
| 3 | Exploring epidemiological risk factors for cerebral amyloid angiopathy: Considerations for monoclonal antibody therapy in people with Alzheimer's disease | 0.5 | 7 | Citations (PDF) |
| 4 | Predicting amyloid beta accumulation in cognitively unimpaired older adults: Cognitive assessments provide no additional utility beyond demographic and genetic factors | 0.5 | 3 | Citations (PDF) |
| 5 | Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing | 3.3 | 7 | Citations (PDF) |
| 6 | Development and validation of a model to predict the progression of Alzheimer’s disease | 1.8 | 0 | Citations (PDF) |
| 7 | Isomerized Aβ in the brain can distinguish the status of amyloidosis in the Alzheimer’s disease spectrum | 9.1 | 1 | Citations (PDF) |
| 8 | The role of autoantibodies in Alzheimer's disease: Pathogenetic connections or epiphenomena? | 0.5 | 1 | Citations (PDF) |
| 9 | The Search for Disease Modification in Parkinson’s Disease—A Review of the Literature | 2.6 | 1 | Citations (PDF) |
| 10 | The role of diet in moderating the relationship between symptoms of depression and brain amyloid load | 0.5 | 4 | Citations (PDF) |
| 11 | Multiomics analysis to evaluate the enrichment of extracellular vesicles from human plasma | 3.6 | 5 | Citations (PDF) |
| 12 | Alpha-synuclein is increased in erythrocytes in parkinson’s disease cases | 3.4 | 2 | Citations (PDF) |
| 13 | Exploring the significance of lipids in Alzheimer's disease and the potential of extracellular vesicles | 3.1 | 11 | Citations (PDF) |
| 14 | Identifying individuals with non‐Alzheimer's disease co‐pathologies: A precision medicine approach to clinical trials in sporadic Alzheimer's disease | 0.5 | 20 | Citations (PDF) |
| 15 | How Can We Use Mathematical Modeling of Amyloid-β in Alzheimer’s Disease Research and Clinical Practices? | 2.6 | 7 | Citations (PDF) |
| 16 | Accuracy of TrUE-Net in comparison to established white matter hyperintensity segmentation methods: An independent validation study | 4.4 | 8 | Citations (PDF) |
| 17 | Lower levels of soluble β-amyloid precursor protein, but not β-amyloid, in the frontal cortex in schizophrenia | 3.1 | 5 | Citations (PDF) |
| 18 | Exploring the association between cancer and cognitive impairment in the Australian Imaging Biomarkers and Lifestyle (AIBL) study | 3.4 | 2 | Citations (PDF) |
| 19 | Inter‐scanner Aβ‐PET harmonization using barrel phantom spatial resolution matching | 2.4 | 3 | Citations (PDF) |
| 20 | Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses | 5.1 | 8 | Citations (PDF) |
| 21 | Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer’s disease | 3.6 | 8 | Citations (PDF) |
| 22 | Exploring the link between comorbidities and Alzheimer's dementia in the Australian Imaging, Biomarker & Lifestyle (AIBL) study | 2.4 | 3 | Citations (PDF) |
| 23 | Association of Basal Forebrain Atrophy With Cognitive Decline in Early Alzheimer Disease | 1.0 | 20 | Citations (PDF) |
| 24 | Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway | 17.1 | 59 | Citations (PDF) |
| 25 | Elucidating the Link Between Anxiety/Depression and Alzheimer’s Dementia in the Australian Imaging Biomarkers and Lifestyle (AIBL) Study | 2.5 | 7 | Citations (PDF) |
| 26 | Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians | 6.5 | 37 | Citations (PDF) |
| 27 | A Comparison of an Australian Observational Longitudinal Alzheimer’s Disease Cohort to Community-Based Australian Data | 2.6 | 2 | Citations (PDF) |
| 28 | A Data-Driven Cognitive Composite Sensitive to Amyloid-β for Preclinical Alzheimer’s Disease | 2.6 | 2 | Citations (PDF) |
| 29 | 3T sodium-MRI as predictor of neurocognition in nondemented older adults: a cross sectional study | 3.6 | 0 | Citations (PDF) |
| 30 | Development and validation of the Florey Dementia Risk Score web-based tool to screen for Alzheimer's disease in primary care | 8.2 | 8 | Citations (PDF) |
| 31 | Using cerebrospinal fluid biomarkers to diagnose Alzheimer’s disease: an Australian perspective | 2.4 | 5 | Citations (PDF) |
| 32 | COCHLEA: Longitudinal Cognitive Performance of Older Adults with Hearing Loss and Cochlear Implants at 4.5-Year Follow-Up | 2.4 | 7 | Citations (PDF) |
| 33 | Quantitative proteomics of tau and Aβ in detergent fractions from Alzheimer's disease brains | 3.8 | 23 | Citations (PDF) |
| 34 | Pre-targeting amyloid-β with antibodies for potential molecular imaging of Alzheimer's disease | 3.4 | 8 | Citations (PDF) |
| 35 | Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL 18F-MK6240 PET study | 9.7 | 35 | Citations (PDF) |
| 36 | Discovery of a Missense Mutation (Q222K) of the
APOE
Gene from the Australian Imaging, Biomarker and Lifestyle Study | 2.3 | 1 | Citations (PDF) |
| 37 | Diagnostic performance of CSF biomarkers in a well-characterized Australian cohort of sporadic Creutzfeldt-Jakob disease | 2.3 | 15 | Citations (PDF) |
| 38 | Exploring the association between tau‐PET and Aβ‐amyloid Centiloid value using deep learning | 0.5 | 0 | Citations (PDF) |
| 39 | Disease progression modelling of Alzheimer’s disease using probabilistic principal components analysis | 4.4 | 15 | Citations (PDF) |
| 40 | Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer’s disease | 3.6 | 21 | Citations (PDF) |
| 41 | Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer’s disease | 7.8 | 14 | Citations (PDF) |
| 42 | Genomic loci influence patterns of structural covariance in the human brain | 7.5 | 29 | Citations (PDF) |
| 43 | Exploring the link between mood disorders and Alzheimer’s disease in the Australian Imaging, Biomarker & Lifestyle Study of Ageing (AIBL) | 0.5 | 0 | Citations (PDF) |
| 44 | Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney | 0.5 | 8 | Citations (PDF) |
| 45 | Deep Generative Medical Image Harmonization for Improving Cross‐Site Generalization in Deep Learning Predictors | 3.4 | 77 | Citations (PDF) |
| 46 | Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives | 2.4 | 32 | Citations (PDF) |
| 47 | No Influence of Age-Related Hearing Loss on Brain Amyloid-β | 2.6 | 15 | Citations (PDF) |
| 48 | Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network | 2.6 | 7 | Citations (PDF) |
| 49 | Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer’s disease | 1.6 | 8 | Citations (PDF) |
| 50 | Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease | 17.6 | 35 | Citations (PDF) |
| 51 | Plasma microRNA vary in association with the progression of Alzheimer's disease | 2.4 | 28 | Citations (PDF) |
| 52 | Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum | 2.4 | 43 | Citations (PDF) |
| 53 | Cerebrospinal fluid Alzheimer disease biomarkers for assessing cognitive and neuropsychiatric symptoms: Expanding the ‘toolkit’ in the psychiatrist’s diagnostic armamentarium | 2.4 | 2 | Citations (PDF) |
| 54 | The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults | 3.9 | 15 | Citations (PDF) |
| 55 | Mesial temporal tau in amyloid-β-negative cognitively normal older persons | 6.5 | 19 | Citations (PDF) |
| 56 | Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer’s disease | 10.9 | 22 | Citations (PDF) |
| 57 | Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF Aβ42 moderates the association between insulin resistance and increased CSF tau levels | 3.4 | 14 | Citations (PDF) |
| 58 | Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques | 1.0 | 162 | Citations (PDF) |
| 59 | Enhanced ion mobility resolution of Abeta isomers from human brain using high-resolution demultiplexing software | 3.4 | 13 | Citations (PDF) |
| 60 | Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume | 4.6 | 33 | Citations (PDF) |
| 61 | Differential Effects of
APOE
and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in Aβ− and Aβ+ Older Adults | 1.0 | 13 | Citations (PDF) |
| 62 | Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study | 3.4 | 11 | Citations (PDF) |
| 63 | Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiologyBrain, 2022, 145, 3594-3607 | 8.4 | 54 | Citations (PDF) |
| 64 | Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease | 3.3 | 5 | Citations (PDF) |
| 65 | Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β | 5.1 | 20 | Citations (PDF) |
| 66 | Avoid or Embrace? Practice Effects in Alzheimer’s Disease Prevention Trials | 3.9 | 13 | Citations (PDF) |
| 67 | Amyloid-β (Aβ)-Related Cerebral Amyloid Angiopathy Causing Lobar Hemorrhage Decades After Childhood Neurosurgery | 5.9 | 18 | Citations (PDF) |
| 68 | Visually Identified Tau
18
F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease | 2.6 | 19 | Citations (PDF) |
| 69 | Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer’s Disease | 4.4 | 8 | Citations (PDF) |
| 70 | Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume | 3.8 | 18 | Citations (PDF) |
| 71 | Nationally Informed Recommendations on Approaching the Detection, Assessment, and Management of Mild Cognitive Impairment | 2.6 | 18 | Citations (PDF) |
| 72 | Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespanBrain, 2022, 145, 4459-4473 | 8.4 | 45 | Citations (PDF) |
| 73 | Mapping the association between tau-PET and Aβ-amyloid-PET using deep learning | 3.4 | 11 | Citations (PDF) |
| 74 | Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals | 1.0 | 76 | Citations (PDF) |
| 75 | Prion disease in Indigenous Australians | 0.8 | 8 | Citations (PDF) |
| 76 | Polygenic score modifies risk for Alzheimer's disease in APOE ε4 homozygotes at phenotypic extremes | 2.4 | 17 | Citations (PDF) |
| 77 | Learning deficit in cognitively normal APOE ε4 carriers with LOW β‐amyloid | 2.4 | 9 | Citations (PDF) |
| 78 | Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations | 2.6 | 8 | Citations (PDF) |
| 79 | Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease | 2.4 | 9 | Citations (PDF) |
| 80 | Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer’s disease | 10.9 | 42 | Citations (PDF) |
| 81 | BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease | 2.3 | 22 | Citations (PDF) |
| 82 | Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies | 4.4 | 37 | Citations (PDF) |
| 83 | Visual Memory Deficits in Middle-Aged
APOE
ɛ
4 Homozygotes Detected Using Unsupervised Cognitive Assessments | 2.6 | 5 | Citations (PDF) |
| 84 | SPON1
Is Associated with Amyloid-β and
APOE
ε4-Related Cognitive Decline in Cognitively Normal Adults | 2.3 | 11 | Citations (PDF) |
| 85 | Deficits in Monocyte Function in Age Related Macular Degeneration: A Novel Systemic Change Associated With the Disease | 2.4 | 16 | Citations (PDF) |
| 86 | Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation | 4.4 | 24 | Citations (PDF) |
| 87 | Genetic testing in dementia‐A medical genetics perspective | 2.2 | 20 | Citations (PDF) |
| 88 | Quantification of N-terminal amyloid-β isoforms reveals isomers are the most abundant form of the amyloid-β peptide in sporadic Alzheimer’s disease | 3.6 | 45 | Citations (PDF) |
| 89 | Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer’s Disease and Neurodegeneration | 2.6 | 5 | Citations (PDF) |
| 90 | Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease | 2.5 | 26 | Citations (PDF) |
| 91 | Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods | 6.5 | 2 | Citations (PDF) |
| 92 | Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults | 3.7 | 12 | Citations (PDF) |
| 93 | Characterization of brain‐derived extracellular vesicle lipids in Alzheimer's disease | 12.6 | 172 | Citations (PDF) |
| 94 | Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition | 2.1 | 9 | Citations (PDF) |
| 95 | Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease | 2.3 | 165 | Citations (PDF) |
| 96 | Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults | 2.6 | 10 | Citations (PDF) |
| 97 | Deaths with Dementia in Indigenous and Non-Indigenous Australians: A Nationwide Study | 2.6 | 4 | Citations (PDF) |
| 98 | A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease | 33.0 | 329 | Citations (PDF) |
| 99 | Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease | 9.1 | 24 | Citations (PDF) |
| 100 | Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study | 17.9 | 59 | Citations (PDF) |
| 101 | The Amyloid-β Pathway in Alzheimer’s Disease | 7.8 | 1,720 | Citations (PDF) |
| 102 | Citrullination of Amyloid-β Peptides in Alzheimer’s Disease | 3.7 | 27 | Citations (PDF) |
| 103 | Relationship between amyloid and tau levels and its impact on tau spreading | 5.5 | 72 | Citations (PDF) |
| 104 | Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease | 1.0 | 24 | Citations (PDF) |
| 105 | A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease | 7.0 | 49 | Citations (PDF) |
| 106 | Genomics of Alzheimer’s disease implicates the innate and adaptive immune systems | 5.5 | 73 | Citations (PDF) |
| 107 | Effects of a physical activity intervention on brain atrophy in older adults at risk of dementia: a randomized controlled trial | 2.1 | 4 | Citations (PDF) |
| 108 | A Paradox in Digital Memory Assessment: Increased Sensitivity With Reduced Difficulty | 2.6 | 6 | Citations (PDF) |
| 109 | Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study | 3.9 | 39 | Citations (PDF) |
| 110 | A deep learning framework identifies dimensional representations of Alzheimer’s Disease from brain structure | 13.7 | 93 | Citations (PDF) |
| 111 | Differential associations of modifiable and non‐modifiable dementia risk factors with memory decline and hippocampal volume loss in Aβ‐ and Aβ+ cognitively normal older adults | 0.5 | 0 | Citations (PDF) |
| 112 | Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI | 3.4 | 32 | Citations (PDF) |
| 113 | A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A ‘C-reactive protein’ for psychiatrists and neurologists? | 2.4 | 59 | Citations (PDF) |
| 114 | Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial | 3.4 | 44 | Citations (PDF) |
| 115 | Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease | 3.4 | 52 | Citations (PDF) |
| 116 | Use of an experimental language acquisition paradigm for standardized neuropsychological assessment of learning: A pilot study in young and older adults | 1.0 | 12 | Citations (PDF) |
| 117 | Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning | 15.9 | 27 | Citations (PDF) |
| 118 | Cerebrospinal fluid neurofilament light chain is elevated in Niemann–Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response | 2.4 | 28 | Citations (PDF) |
| 119 | Harmonization of large MRI datasets for the analysis of brain imaging patterns throughout the lifespan | 4.4 | 523 | Citations (PDF) |
| 120 | Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer’s Disease | 2.6 | 26 | Citations (PDF) |
| 121 | Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease | 3.6 | 20 | Citations (PDF) |
| 122 | Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease | 3.3 | 27 | Citations (PDF) |
| 123 | Intra-cerebral haemorrhage but not neurodegenerative disease appears over-represented in deaths of Australian cadaveric pituitary hormone recipients | 1.6 | 3 | Citations (PDF) |
| 124 | Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer’s disease | 13.7 | 138 | Citations (PDF) |
| 125 | Evaluation of GammaH2AX in Buccal Cells as a Molecular Biomarker of DNA Damage in Alzheimer’s Disease in the AIBL Study of Ageing | 2.6 | 6 | Citations (PDF) |
| 126 | Sequence of Alzheimer disease biomarker changes in cognitively normal adults | 1.0 | 49 | Citations (PDF) |
| 127 | Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer’s Disease Patients and Correlates with Cognitive Performance | 2.6 | 14 | Citations (PDF) |
| 128 | Association of deficits in short-term learning and Aβ and hippocampal volume in cognitively normal adults | 1.0 | 53 | Citations (PDF) |
| 129 | Longitudinal evaluation of the natural history of amyloid-β in plasma and brain | 3.6 | 32 | Citations (PDF) |
| 130 | Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer’s Disease | 2.6 | 45 | Citations (PDF) |
| 131 | Morphometric Changes to Corneal Dendritic Cells in Individuals With Mild Cognitive Impairment | 2.7 | 31 | Citations (PDF) |
| 132 | The anti‐amyloid treatment in asymptomatic Alzheimer’s disease (A4) study: Report of screening and recruitment characteristics of the Melbourne composite site | 0.5 | 2 | Citations (PDF) |
| 133 | Risk factors for falls in preclinical and prodromal Alzheimer’s disease and dementia due to Alzheimer’s disease: Findings from the Australian Imaging, Biomarker and Lifestyle study of ageing (AIBL) | 0.5 | 0 | Citations (PDF) |
| 134 | The function and composition of brain tissue derived exosomes in human Alzheimer’s disease | 0.5 | 0 | Citations (PDF) |
| 135 | Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer’s disease and controls | 6.5 | 55 | Citations (PDF) |
| 136 | Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration | 2.6 | 15 | Citations (PDF) |
| 137 | Small RNA fingerprinting of Alzheimer's disease frontal cortex extracellular vesicles and their comparison with peripheral extracellular vesicles | 12.6 | 90 | Citations (PDF) |
| 138 | Maximizing Safety in the Conduct of Alzheimer’s Disease Fluid Biomarker Research in the Era of COVID-19 | 2.6 | 8 | Citations (PDF) |
| 139 | Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer’s Disease | 2.6 | 36 | Citations (PDF) |
| 140 | Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology | 6.5 | 29 | Citations (PDF) |
| 141 | A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease | 33.0 | 578 | Citations (PDF) |
| 142 | Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease | 2.4 | 52 | Citations (PDF) |
| 143 | Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease | 6.5 | 151 | Citations (PDF) |
| 144 | MRI signatures of brain age and disease over the lifespan based on a deep brain network and 14 468 individuals worldwideBrain, 2020, 143, 2312-2324 | 8.4 | 375 | Citations (PDF) |
| 145 | Optimizing red blood cell protein extraction for biomarker quantitation with mass spectrometry | 3.4 | 14 | Citations (PDF) |
| 146 | Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimer’s Disease | 3.9 | 8 | Citations (PDF) |
| 147 | Total Aβ
42
/Aβ
40
ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis | 1.0 | 188 | Citations (PDF) |
| 148 | Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging | 6.5 | 71 | Citations (PDF) |
| 149 | Comorbidity of Cerebrovascular and Alzheimer’s Disease in Aging | 2.6 | 10 | Citations (PDF) |
| 150 | Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer’s disease | 1.9 | 9 | Citations (PDF) |
| 151 | Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults | 0.4 | 39 | Citations (PDF) |
| 152 | Determining clinically meaningful decline in preclinical Alzheimer disease | 1.0 | 138 | Citations (PDF) |
| 153 | Genetic resilience to Alzheimer's disease in APOE ε4 homozygotes: A systematic review | 0.5 | 33 | Citations (PDF) |
| 154 | Rates of age‐ and amyloid β‐associated cortical atrophy in older adults with superior memory performance | 2.4 | 25 | Citations (PDF) |
| 155 | Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease | 13.7 | 280 | Citations (PDF) |
| 156 | Using subjective cognitive decline to identify high global amyloid in community‐based samples: A cross‐cohort study | 2.4 | 25 | Citations (PDF) |
| 157 | Characterization of the metal status of natively purified alpha-synuclein from human blood, brain tissue, or recombinant sources using size exclusion ICP-MS reveals no significant binding of Cu, Fe or Zn | 2.5 | 15 | Citations (PDF) |
| 158 | Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease | 33.0 | 836 | Citations (PDF) |
| 159 | Klotho allele status is not associated with Aβ and APOE ε4–related cognitive decline in preclinical Alzheimer's disease | 3.4 | 28 | Citations (PDF) |
| 160 | Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS | 1.8 | 40 | Citations (PDF) |
| 161 | Avoiding methodological bias in studies of amyloid imaging results disclosure | 6.5 | 3 | Citations (PDF) |
| 162 | COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults | 2.1 | 5 | Citations (PDF) |
| 163 | Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer’s diseaseBrain, 2019, 142, 1429-1440 | 8.4 | 44 | Citations (PDF) |
| 164 | ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes | 1.0 | 93 | Citations (PDF) |
| 165 | To What Extent Does Age at Death Account for Sex Differences in Rates of Mortality From Alzheimer Disease? | 3.3 | 44 | Citations (PDF) |
| 166 | Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies | 2.4 | 118 | Citations (PDF) |
| 167 | Sensitivity of a Preclinical Alzheimer’s Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer’s disease | 1.0 | 29 | Citations (PDF) |
| 168 | A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease | 10.9 | 74 | Citations (PDF) |
| 169 | IC‐P‐167: AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON BRAIN SURFACE | 0.5 | 2 | Citations (PDF) |
| 170 | IC‐P‐004: CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES | 0.5 | 0 | Citations (PDF) |
| 171 | IC‐P‐017: AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS | 0.5 | 0 | Citations (PDF) |
| 172 | Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition | 3.4 | 22 | Citations (PDF) |
| 173 | An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations | 17.1 | 338 | Citations (PDF) |
| 174 | A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer’s Disease: The AIBL Active-Study | 2.6 | 28 | Citations (PDF) |
| 175 | Seizures as an early symptom of autosomal dominant Alzheimer's disease | 3.4 | 37 | Citations (PDF) |
| 176 | The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease | 7.8 | 79 | Citations (PDF) |
| 177 | Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults. | 1.6 | 22 | Citations (PDF) |
| 178 | Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms | 2.6 | 24 | Citations (PDF) |
| 179 | Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer’s diseaseBrain, 2018, 141, 1186-1200 | 8.4 | 103 | Citations (PDF) |
| 180 | Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden | 5.2 | 135 | Citations (PDF) |
| 181 | Preferential degradation of cognitive networks differentiates Alzheimer’s disease from ageingBrain, 2018, 141, 1486-1500 | 8.4 | 96 | Citations (PDF) |
| 182 | Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer’s disease | 0.4 | 15 | Citations (PDF) |
| 183 | Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study | 17.9 | 550 | Citations (PDF) |
| 184 | Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β | 2.6 | 56 | Citations (PDF) |
| 185 | Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions | 28.6 | 431 | Citations (PDF) |
| 186 | High performance plasma amyloid-β biomarkers for Alzheimer’s disease | 37.9 | 1,613 | Citations (PDF) |
| 187 | KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden | 3.4 | 36 | Citations (PDF) |
| 188 | Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease | 17.6 | 80 | Citations (PDF) |
| 189 | Amyloid burden and incident depressive symptoms in preclinical Alzheimer’s disease | 4.5 | 38 | Citations (PDF) |
| 190 | Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies | 2.6 | 120 | Citations (PDF) |
| 191 | Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years | 1.3 | 26 | Citations (PDF) |
| 192 | CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldt–Jakob disease diagnosis while transitioning to next generation diagnostics | 1.6 | 13 | Citations (PDF) |
| 193 | Trajectories of depressive and anxiety symptoms in older adults: a 6‐year prospective cohort study | 2.2 | 31 | Citations (PDF) |
| 194 | P2‐364: TAU IMAGING IN ALZHEIMER'S DISEASE WITH [F‐18]‐MK6240, A SECOND GENERATION SELECTIVE TAU TRACER | 0.5 | 0 | Citations (PDF) |
| 195 | IC‐P‐223: TO TAU OR TO MAO‐B? MOST OF THE [F‐18]‐THK5351 SIGNAL IS BLOCKED BY SELEGILINE | 0.5 | 0 | Citations (PDF) |
| 196 | O4‐09‐01: COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL Aβ‐AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD | 0.5 | 0 | Citations (PDF) |
| 197 | P3‐494: EXAMINING THE INFLUENCE OF UNDETECTED ATN NEUROPATHOLOGY ON COGNITIVE AGING TRAJECTORIES | 0.5 | 0 | Citations (PDF) |
| 198 | P3‐620: INCREASED PROTEIN AND FIBRE INTAKE IS ASSOCIATED WITH HIGHER PERFORMANCE IN THE AIBL PACC SCORE IN COGNITIVELY NORMAL ADULTS: AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE (AIBL) STUDY | 0.5 | 0 | Citations (PDF) |
| 199 | O1‐04‐01: PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAYS: RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY | 0.5 | 0 | Citations (PDF) |
| 200 | IC‐P‐008: VISUAL ASSESSMENT OF β‐AMYLOID PET SCAN IS IMPROVED BY CAPAIBL | 0.5 | 0 | Citations (PDF) |
| 201 | Utility of an Alzheimer’s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer’s Disease: A Prospective Longitudinal Study | 2.6 | 47 | Citations (PDF) |
| 202 | CSF
progranulin increases in the course of Alzheimer's disease and is associated with
sTREM
2, neurodegeneration and cognitive decline | 7.1 | 97 | Citations (PDF) |
| 203 | A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer’s Disease | 3.9 | 31 | Citations (PDF) |
| 204 | Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic | 28.6 | 636 | Citations (PDF) |
| 205 | White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s diseaseBrain, 2018, 141, 3065-3080 | 8.4 | 168 | Citations (PDF) |
| 206 | Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing | 5.2 | 83 | Citations (PDF) |
| 207 | Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults | 2.6 | 26 | Citations (PDF) |
| 208 | Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well‐characterized cohorts | 0.5 | 262 | Citations (PDF) |
| 209 | Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography | 2.6 | 48 | Citations (PDF) |
| 210 | Ocular Biomarkers of Alzheimer's Disease: The Role of Anterior Eye and Potential Future Directions 2018, 59, 3554 | | 35 | Citations (PDF) |
| 211 | Effect ofBDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease | 6.6 | 30 | Citations (PDF) |
| 212 | The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults | 2.3 | 19 | Citations (PDF) |
| 213 | Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer’s Disease | 2.6 | 23 | Citations (PDF) |
| 214 | Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL | 4.4 | 147 | Citations (PDF) |
| 215 | White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer’s disease | 2.3 | 70 | Citations (PDF) |
| 216 | Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease | 3.4 | 16 | Citations (PDF) |
| 217 | Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer’s disease, mild cognitive impairment, and healthy aging: A longitudinal study. | 1.5 | 10 | Citations (PDF) |
| 218 | Amyloid burden and incident depressive symptoms in cognitively normal older adults | 2.2 | 67 | Citations (PDF) |
| 219 | Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer’s Disease | 2.6 | 11 | Citations (PDF) |
| 220 | Cognitive impairment and decline in cognitively normal older adults with high amyloid‐β: A meta‐analysis | 2.4 | 177 | Citations (PDF) |
| 221 | Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer’s Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) | 2.6 | 63 | Citations (PDF) |
| 222 | APOE ɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults | 2.6 | 10 | Citations (PDF) |
| 223 | Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study | 2.6 | 21 | Citations (PDF) |
| 224 | The APOE ε4 Allele Is Associated with Lower Selenium Levels in the Brain: Implications for Alzheimer’s Disease | 3.7 | 54 | Citations (PDF) |
| 225 | Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort | 2.4 | 31 | Citations (PDF) |
| 226 | Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease | 3.4 | 47 | Citations (PDF) |
| 227 | Characterization and Identification of Dityrosine Cross-Linked Peptides Using Tandem Mass Spectrometry | 6.5 | 82 | Citations (PDF) |
| 228 | Effect of
APOE
Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals | 2.6 | 39 | Citations (PDF) |
| 229 | A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium | 2.4 | 35 | Citations (PDF) |
| 230 | Biochemically-defined pools of amyloid-β in sporadic Alzheimer’s disease: correlation with amyloid PETBrain, 2017, 140, 1486-1498 | 8.4 | 159 | Citations (PDF) |
| 231 | Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner | 2.6 | 13 | Citations (PDF) |
| 232 | Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging | 0.4 | 58 | Citations (PDF) |
| 233 | A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain | 28.6 | 742 | Citations (PDF) |
| 234 | Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals | 2.4 | 170 | Citations (PDF) |
| 235 | A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort | 3.4 | 28 | Citations (PDF) |
| 236 | Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults | 3.4 | 83 | Citations (PDF) |
| 237 | A rigorous method to enrich for exosomes from brain tissue | 12.6 | 309 | Citations (PDF) |
| 238 | [O3–09–01]: IMPLEMENTING THE CENTILOID TRANSFORMATION FOR 18F‐FLORBETABEN AND 18F‐NAV4694 USING CAPAIBL | 0.5 | 1 | Citations (PDF) |
| 239 | [P1–607]: SELF‐REPORTED PHYSICAL ACTIVITY IS ASSOCIATED WITH TAU BURDEN AS MEASURED BY PET | 0.5 | 0 | Citations (PDF) |
| 240 | 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids | 5.5 | 156 | Citations (PDF) |
| 241 | Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness | 2.4 | 24 | Citations (PDF) |
| 242 | The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease | 5.0 | 98 | Citations (PDF) |
| 243 | Aβ-amyloid and Tau Imaging in Dementia | 4.9 | 106 | Citations (PDF) |
| 244 | Plasma Cortisol, Brain Amyloid-β, and Cognitive Decline in Preclinical Alzheimer’s Disease: A 6-Year Prospective Cohort Study | 1.2 | 44 | Citations (PDF) |
| 245 | [P2–535]: DIFFERENCES IN LONGEVITY AND DEATH CERTIFICATION ACCOUNT FOR SEX DISPARITY IN DEMENTIA MORTALITY RATES | 0.5 | 0 | Citations (PDF) |
| 246 | [P3–224]: THE INFLUENCE OF LOW‐DENSITY LIPOPROTEINS ON NEOCORTICAL AMYLOID LOAD IN THE AUSTRALIAN IMAGING BIOMARKER AND LIFESTYLE STUDY | 0.5 | 0 | Citations (PDF) |
| 247 | [P3–243]: A MASS SPECTROMETRY‐BASED DISCOVERY AND REPLICATION OF A MULTI‐ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY | 0.5 | 0 | Citations (PDF) |
| 248 | [P3–462]: CONSIDERATION OF PRECLINICAL AD FROM THE PERSPECTIVE OF NORMAL AGING: AMYLOID‐β RELATED CHANGES IN FLUID AND CRYSTALLIZED INTELLIGENCE IN A ROBUST SAMPLE OF HEALTHY OLDER ADULTS | 0.5 | 0 | Citations (PDF) |
| 249 | [P4–134]: INSULIN RESISTANCE IS ASSOCIATED WITH REDUCTIONS IN SPECIFIC COGNITIVE DOMAINS AND INCREASES IN CSF TAU IN COGNITIVELY NORMAL ADULTS | 0.5 | 0 | Citations (PDF) |
| 250 | [P4–136]: IL‐10 AND IL‐12/23P40 ARE JOINTLY ASSOCIATED AS PREDICTORS OF Aβ‐AMYLOID LOAD IN A BROADER BLOOD‐BASED BIOMARKER PANEL | 0.5 | 1 | Citations (PDF) |
| 251 | [P4–255]: CORTICAL CEREBRAL MICROINFARCTS ON 3T MRI IN ALZHEIMER's DISEASE AND MILD COGNITIVE IMPAIRMENT | 0.5 | 1 | Citations (PDF) |
| 252 | [P1–416]: CSF TOTAL TAU AS A BIOMARKER FOR NEURONAL INJURY IN ALZHEIMER's DISEASE: ALIGNING RATES OF CSF CHANGE WITH RATES OF HIPPOCAMPAL AND CORTICAL GRAY MATTER ATROPHY | 0.5 | 0 | Citations (PDF) |
| 253 | [P2–263]: GRAPHICAL NETWORK ANALYSES INFORMS PET Aβ‐AMYLOID BIOMARKER DISCOVERY VIA QUANTIFICATION OF INDIVIDUAL PEPTIDE CONNECTIONS | 0.5 | 0 | Citations (PDF) |
| 254 | [P4–561]: MEDITERRANEAN DIET ADHERENCE IS ASSOCIATED WITH ATTENUATED CORTICAL THINNING IN AN AUSTRALIAN STUDY OF AGEING | 0.5 | 0 | Citations (PDF) |
| 255 | [P1–444]: QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN Aβ+ ELDERLY CONTROLS AND ALZHEIMER's DISEASE PATIENTS | 0.5 | 2 | Citations (PDF) |
| 256 | Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive declineBrain, 2017, 140, 2112-2119 | 8.4 | 278 | Citations (PDF) |
| 257 | A Multi-Cohort Study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer’s Disease | 2.6 | 43 | Citations (PDF) |
| 258 | Subjective Memory Complaints in
APOE
ɛ
4 Carriers are Associated with High Amyloid-β Burden | 2.6 | 53 | Citations (PDF) |
| 259 | Impact of Mild Head Injury on Neuropsychological Performance in Healthy Older Adults: Longitudinal Assessment in the AIBL Cohort | 3.9 | 16 | Citations (PDF) |
| 260 | Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group | 2.3 | 53 | Citations (PDF) |
| 261 | P4‐388: XANAMEMTM: A Novel 11B‐HSD1 Inhibitor with Potential to Provide Durable Symptomatic and Disease Modifying Benefits in Alzheimer’S Disease | 0.5 | 1 | Citations (PDF) |
| 262 | Aβ-related memory decline in
APOE
ε4 noncarriers | 1.0 | 42 | Citations (PDF) |
| 263 | Apolipoprotein C-II Adopts Distinct Structures in Complex with Micellar and Submicellar Forms of the Amyloid-Inhibiting Lipid-Mimetic Dodecylphosphocholine | 2.2 | 5 | Citations (PDF) |
| 264 | Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia | 2.4 | 21 | Citations (PDF) |
| 265 | The Neurobiology and Age-Related Prevalence of the ε4 Allele of Apolipoprotein E in Alzheimer’s Disease Cohorts | 2.4 | 107 | Citations (PDF) |
| 266 | BDNFVal66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer’s diseaseBrain, 2016, 139, 2766-2777 | 8.4 | 78 | Citations (PDF) |
| 267 | A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease | 2.4 | 45 | Citations (PDF) |
| 268 | Predicting Alzheimer disease from a blood-based biomarker profile | 1.0 | 30 | Citations (PDF) |
| 269 | Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study | 17.9 | 194 | Citations (PDF) |
| 270 | Magnetic Resonance Imaging of Vascular Contributions to Cognitive Impairment and Dementia | 2.4 | 9 | Citations (PDF) |
| 271 | Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer’s disease | 9.1 | 57 | Citations (PDF) |
| 272 | Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease | 3.4 | 45 | Citations (PDF) |
| 273 | Neurological manifestations of autosomal dominant familial Alzheimer’s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) | 17.9 | 114 | Citations (PDF) |
| 274 | The Relationship between Sleep Quality and Brain Amyloid BurdenSleep, 2016, 39, 1063-1068 | 0.9 | 152 | Citations (PDF) |
| 275 | Rubidium and potassium levels are altered in Alzheimer’s disease brain and blood but not in cerebrospinal fluid | 5.0 | 57 | Citations (PDF) |
| 276 | Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in Alzheimer's disease frontal cortex | 4.4 | 63 | Citations (PDF) |
| 277 | Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z‐scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score | 2.4 | 89 | Citations (PDF) |
| 278 | Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging | 2.4 | 32 | Citations (PDF) |
| 279 | White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network | 6.6 | 519 | Citations (PDF) |
| 280 | Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons | 2.2 | 80 | Citations (PDF) |
| 281 | Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s diseaseBrain, 2016, 139, 2528-2539 | 8.4 | 71 | Citations (PDF) |
| 282 | Amyloid-β Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults | 2.6 | 66 | Citations (PDF) |
| 283 | Alzheimer's disease | 46.9 | 1,669 | Citations (PDF) |
| 284 | Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer’s disease. | 1.6 | 51 | Citations (PDF) |
| 285 | Alzheimer’s Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study | 2.6 | 56 | Citations (PDF) |
| 286 | Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer’s Disease Risk | 2.6 | 8 | Citations (PDF) |
| 287 | Peripheral α-Defensins 1 and 2 are Elevated in Alzheimer's Disease | 2.6 | 16 | Citations (PDF) |
| 288 | Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer’s Disease Trials: An AIBL Study | 2.6 | 31 | Citations (PDF) |
| 289 | A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease | 6.5 | 13 | Citations (PDF) |
| 290 | Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology | 6.5 | 17 | Citations (PDF) |
| 291 | Semi‐automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration | 3.4 | 9 | Citations (PDF) |
| 292 | Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer’s Disease: What are the Roadblocks and How Can They Be Overcome? | 2.6 | 104 | Citations (PDF) |
| 293 | Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months | 2.3 | 22 | Citations (PDF) |
| 294 | Factors Associated With the Onset and Persistence of Post–Lumbar Puncture Headache | 17.6 | 80 | Citations (PDF) |
| 295 | O3‐03‐04: Characteristics of the neighborhood built environment are associated with MRI brain volumetric and amyloid beta burden measures: Findings from the australian imaging, biomarkers, and lifestyle (AIBL) study | 0.5 | 0 | Citations (PDF) |
| 296 | Bayesian Graphical Network Analyses Reveal Complex Biological Interactions Specific to Alzheimer's Disease | 2.6 | 14 | Citations (PDF) |
| 297 | Reduction of p75 neurotrophin receptor ameliorates the cognitive deficits in a model of Alzheimer's disease | 3.4 | 28 | Citations (PDF) |
| 298 | Decreased Plasma Iron in Alzheimer’s Disease Is Due to Transferrin Desaturation | 3.7 | 81 | Citations (PDF) |
| 299 | APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease | 3.4 | 79 | Citations (PDF) |
| 300 | Comparison of MR-less PiB SUVR quantification methods | 3.4 | 132 | Citations (PDF) |
| 301 | High Order W02-Reactive Stable Oligomers of Amyloid-β are Produced in vivo and in vitro via Dialysis and Filtration of Synthetic Amyloid-β Monomer | 2.6 | 2 | Citations (PDF) |
| 302 | Early behavioural changes in familial Alzheimer’s disease in the Dominantly Inherited Alzheimer NetworkBrain, 2015, 138, 1036-1045 | 8.4 | 76 | Citations (PDF) |
| 303 | Stabilization of Nontoxic Aβ-Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease | 3.7 | 72 | Citations (PDF) |
| 304 | Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and A Accumulation in Cognitively Normal Older Adults and Adults with MCI | 0.4 | 48 | Citations (PDF) |
| 305 | Longitudinal cognitive decline in the AIBL cohort: The role of APOE ε4 status | 1.7 | 31 | Citations (PDF) |
| 306 | Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing | 3.4 | 77 | Citations (PDF) |
| 307 | Amyloid-β, Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease | 12.4 | 204 | Citations (PDF) |
| 308 | Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort | 6.5 | 24 | Citations (PDF) |
| 309 | Glycosaminoglycan sulfation determines the biochemical properties of prion protein aggregates | 2.2 | 14 | Citations (PDF) |
| 310 | Small angle X-ray scattering analysis of Cu2+-induced oligomers of the Alzheimer's amyloid β peptide | 2.5 | 27 | Citations (PDF) |
| 311 | Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease | 1.0 | 32 | Citations (PDF) |
| 312 | Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β-Amyloid Toxicity and Are Mediated by Tau | 6.0 | 62 | Citations (PDF) |
| 313 | Traumatic brain injury induces elevation of Co in the human brain | 2.5 | 15 | Citations (PDF) |
| 314 | Tau imaging: early progress and future directions | 17.9 | 475 | Citations (PDF) |
| 315 | Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study | 6.3 | 95 | Citations (PDF) |
| 316 | Alpha-synuclein oligomers and fibrils originate in two distinct conformer pools: a small angle X-ray scattering and ensemble optimisation modelling study | 3.1 | 29 | Citations (PDF) |
| 317 | MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET | 2.3 | 48 | Citations (PDF) |
| 318 | Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer’s Disease: A Preliminary Study | 2.3 | 82 | Citations (PDF) |
| 319 | Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations | 2.3 | 203 | Citations (PDF) |
| 320 | C-terminal peptides modelling constitutive PrPC processing demonstrate ameliorated toxicity predisposition consequent to α-cleavage | 3.8 | 12 | Citations (PDF) |
| 321 | Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease | 12.5 | 369 | Citations (PDF) |
| 322 | Incidence of cerebral microbleeds in preclinical Alzheimer disease | 1.0 | 146 | Citations (PDF) |
| 323 | Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease | 17.6 | 130 | Citations (PDF) |
| 324 | Guanidine hydrochloride denaturation of dopamine-induced α-synuclein oligomers: A small-angle X-ray scattering study | 2.6 | 10 | Citations (PDF) |
| 325 | Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PETBrain, 2014, 137, 1762-1771 | 8.4 | 248 | Citations (PDF) |
| 326 | Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s diseaseBrain, 2014, 137, 221-231 | 8.4 | 209 | Citations (PDF) |
| 327 | Decreased serum zinc is an effect of ageing and not Alzheimer's disease | 2.5 | 44 | Citations (PDF) |
| 328 | An iron–dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta | 7.1 | 109 | Citations (PDF) |
| 329 | Influence of
BDNF
Val66Met on the relationship between physical activity and brain volume | 1.0 | 65 | Citations (PDF) |
| 330 | Design of non-aggregating variants of Aβ peptide | 2.1 | 0 | Citations (PDF) |
| 331 | In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease | 5.5 | 161 | Citations (PDF) |
| 332 | Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis | 3.7 | 200 | Citations (PDF) |
| 333 | Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts | 2.6 | 88 | Citations (PDF) |
| 334 | Symptom onset in autosomal dominant Alzheimer disease | 1.0 | 503 | Citations (PDF) |
| 335 | Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies | 4.4 | 90 | Citations (PDF) |
| 336 | Pathogenic Mutations within the Hydrophobic Domain of the Prion Protein Lead to the Formation of Protease-Sensitive Prion Species with Increased Lethality | 3.6 | 21 | Citations (PDF) |
| 337 | An increased neutrophil–lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation | 2.3 | 114 | Citations (PDF) |
| 338 | Plasma Amyloid-β Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden | 2.6 | 47 | Citations (PDF) |
| 339 | Update on creutzfeldt-jakob disease | 1.6 | 0 | Citations (PDF) |
| 340 | Personal Memory Function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing | 2.6 | 10 | Citations (PDF) |
| 341 | 18F-florbetaben Aβ imaging in mild cognitive impairment | 6.5 | 53 | Citations (PDF) |
| 342 | Progress Towards a Consensus on Biomarkers for Alzheimer‘S Disease: A Review of Peripheral Analytes | 1.5 | 30 | Citations (PDF) |
| 343 | Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease | 7.5 | 381 | Citations (PDF) |
| 344 | Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer’s disease | 2.5 | 217 | Citations (PDF) |
| 345 | Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing | 6.6 | 211 | Citations (PDF) |
| 346 | Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry | 2.5 | 44 | Citations (PDF) |
| 347 | Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease | 2.6 | 51 | Citations (PDF) |
| 348 | Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study | 17.9 | 2,161 | Citations (PDF) |
| 349 | Mixed Ligand Cu2+Complexes of a Model Therapeutic with Alzheimer’s Amyloid-β Peptide and Monoamine Neurotransmitters | 4.6 | 58 | Citations (PDF) |
| 350 | BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease | 3.4 | 119 | Citations (PDF) |
| 351 | Cross-sectional and Longitudinal Analysis of the Relationship Between Aβ Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease | 17.6 | 188 | Citations (PDF) |
| 352 | Development of a Platinum Complex as an anti‐Amyloid Agent for the Therapy of Alzheimer’s Disease | 14.4 | 66 | Citations (PDF) |
| 353 | Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid-β | 2.6 | 44 | Citations (PDF) |
| 354 | Lack of reliable evidence for a distinctive ε4−related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle StudyBrain, 2013, 136, 2201-2216 | 8.4 | 33 | Citations (PDF) |
| 355 | The pattern of atrophy in familial Alzheimer disease | 1.0 | 78 | Citations (PDF) |
| 356 | Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS) | 0.4 | 107 | Citations (PDF) |
| 357 | The Women's Healthy Ageing Project: Fertile ground for investigation of healthy participants ‘at risk’ for dementia | 2.6 | 20 | Citations (PDF) |
| 358 | Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia | 5.1 | 179 | Citations (PDF) |
| 359 | Cognitive Decline in Adults with Amnestic Mild Cognitive Impairment and High Amyloid-β: Prodromal Alzheimer's Disease? | 2.6 | 35 | Citations (PDF) |
| 360 | Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer’s disease. | 1.6 | 36 | Citations (PDF) |
| 361 | Development of a Platinum Complex as an anti‐Amyloid Agent for the Therapy of Alzheimer’s Disease | 1.4 | 8 | Citations (PDF) |
| 362 | Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid-β | 2.6 | 70 | Citations (PDF) |
| 363 | Inhibition of ??-Secretase as a Therapeutic Intervention for Alzheimer???s Disease | 6.3 | 58 | Citations (PDF) |
| 364 | Biochemistry of Amyloid -Protein and Amyloid Deposits in Alzheimer Disease | 6.6 | 500 | Citations (PDF) |
| 365 | Small Amphipathic Molecules Modulate Secondary Structure and Amyloid Fibril-forming Kinetics of Alzheimer Disease Peptide Aβ1–42 | 2.2 | 46 | Citations (PDF) |
| 366 | Developing an international network for Alzheimer’s research: the Dominantly Inherited Alzheimer Network | 0.3 | 210 | Citations (PDF) |
| 367 | Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB–PET longitudinal studyBrain, 2012, 135, 2126-2139 | 8.4 | 252 | Citations (PDF) |
| 368 | The Prion Protein Preference of Sporadic Creutzfeldt-Jakob Disease Subtypes | 2.2 | 9 | Citations (PDF) |
| 369 | Stronger effect of amyloid load than
APOE
genotype on cognitive decline in healthy older adults | 1.0 | 97 | Citations (PDF) |
| 370 | Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease | 34.5 | 3,658 | Citations (PDF) |
| 371 | Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease | 6.8 | 402 | Citations (PDF) |
| 372 | Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study | 1.0 | 137 | Citations (PDF) |
| 373 | The Challenges of Tau Imaging | 0.5 | 93 | Citations (PDF) |
| 374 | sAPPα rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury | 3.8 | 65 | Citations (PDF) |
| 375 | The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease | 9.3 | 179 | Citations (PDF) |
| 376 | Generating recombinant C-terminal prion protein fragments of exact native sequence | 3.5 | 3 | Citations (PDF) |
| 377 | Evaluation of the effects of treatment with sAPPα on functional and histological outcome following controlled cortical impact injury in mice | 1.9 | 18 | Citations (PDF) |
| 378 | In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer | 0.3 | 60 | Citations (PDF) |
| 379 | Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease | 14.1 | 239 | Citations (PDF) |
| 380 | Prion subcellular fractionation reveals infectivity spectrum, with a high titre-low PrPres level disparity | 14.1 | 15 | Citations (PDF) |
| 381 | Variability in Blood-Based Amyloid-β Assays: The Need for Consensus on Pre-Analytical Processing | 2.6 | 36 | Citations (PDF) |
| 382 | Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease | 5.5 | 187 | Citations (PDF) |
| 383 | The role of metallobiology and amyloid‐β peptides in Alzheimer’s disease | 3.8 | 254 | Citations (PDF) |
| 384 | Elevated labile Cu is associated with oxidative pathology in Alzheimer disease | 3.7 | 172 | Citations (PDF) |
| 385 | Characterisation of the effect of knockout of the amyloid precursor protein on outcome following mild traumatic brain injury | 2.5 | 41 | Citations (PDF) |
| 386 | Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease | 2.2 | 19 | Citations (PDF) |
| 387 | Correct Heteroduplex Formation for Mutation Detection Analysis | 0.4 | 0 | Citations (PDF) |
| 388 | Olfactory Deficits and Amyloid-β Burden in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Aging: A PiB PET Study | 2.6 | 85 | Citations (PDF) |
| 389 | Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study | 2.6 | 90 | Citations (PDF) |
| 390 | Independent contribution of temporal β-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer’s diseaseBrain, 2011, 134, 798-807 | 8.4 | 137 | Citations (PDF) |
| 391 | Investigation of Matrix Metalloproteinases, MMP-2 and MMP-9, in Plasma Reveals a Decrease of MMP-2 in Alzheimer's Disease | 2.6 | 63 | Citations (PDF) |
| 392 | Amyloid-β: The seeds of darkness | 2.6 | 26 | Citations (PDF) |
| 393 | Iatrogenic Creutzfeldt–Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients? | 1.7 | 0 | Citations (PDF) |
| 394 | Increasing the Predictive Accuracy of Amyloid-β Blood-Borne Biomarkers in Alzheimer's Disease | 2.6 | 17 | Citations (PDF) |
| 395 | Optical Imaging Detects Apoptosis in the Brain and Peripheral Organs of Prion-Infected Mice | 1.8 | 17 | Citations (PDF) |
| 396 | Gene Knockout of tau Expression Does Not Contribute to the Pathogenesis of Prion Disease | 1.8 | 13 | Citations (PDF) |
| 397 | Overview and recent advances in neuropathology. Part 2: Neurodegeneration | 1.6 | 11 | Citations (PDF) |
| 398 | The Alzheimer’s therapeutic PBT2 promotes amyloid‐β degradation and GSK3 phosphorylation via a metal chaperone activity | 3.8 | 175 | Citations (PDF) |
| 399 | Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study | 1.7 | 149 | Citations (PDF) |
| 400 | Acute exposure to prion infection induces transient oxidative stress progressing to be cumulatively deleterious with chronic propagation in vitro | 3.7 | 34 | Citations (PDF) |
| 401 | The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains | 2.5 | 71 | Citations (PDF) |
| 402 | Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease | 6.6 | 801 | Citations (PDF) |
| 403 | Decreased expression of GGA3 Protein in Alzheimer's disease frontal cortex and increased co-distribution of BACE with the amyloid precursor protein | 5.1 | 39 | Citations (PDF) |
| 404 | Copper Promotes the Trafficking of the Amyloid Precursor Protein | 2.2 | 96 | Citations (PDF) |
| 405 | Crystal Structure of the Amyloid-β p3 Fragment Provides a Model for Oligomer Formation in Alzheimer's Disease | 3.7 | 102 | Citations (PDF) |
| 406 | Amyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other Dementias | 5.1 | 353 | Citations (PDF) |
| 407 | Relationship between atrophy and β‐amyloid deposition in Alzheimer disease | 6.6 | 356 | Citations (PDF) |
| 408 | Histidine 14 Modulates Membrane Binding and Neurotoxicity of the Alzheimer's Disease Amyloid-β Peptide | 2.6 | 33 | Citations (PDF) |
| 409 | Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging | 2.6 | 131 | Citations (PDF) |
| 410 | PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses | 2.6 | 390 | Citations (PDF) |
| 411 | The structure of dopamine induced α-synuclein oligomers | 2.0 | 92 | Citations (PDF) |
| 412 | α-Synuclein Transgenic Mice Reveal Compensatory Increases in Parkinson's Disease-Associated Proteins DJ-1 and Parkin and Have Enhanced α-Synuclein and PINK1 Levels After Rotenone Treatment | 2.4 | 38 | Citations (PDF) |
| 413 | Zinc induces depletion and aggregation of endogenous TDP-43 | 3.7 | 60 | Citations (PDF) |
| 414 | Manganese chelation therapy extends survival in a mouse model of M1000 prion disease | 3.8 | 37 | Citations (PDF) |
| 415 | Iatrogenic Creutzfeldt–Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients? | 1.7 | 10 | Citations (PDF) |
| 416 | Glycosaminoglycan Sulphation Affects the Seeded Misfolding of a Mutant Prion Protein | 2.3 | 21 | Citations (PDF) |
| 417 | 11C-PiB PET ABri Imaging in Worster-Drought Syndrome (Familial British Dementia): A Case Report | 2.6 | 16 | Citations (PDF) |
| 418 | Conservation of a Glycine-rich Region in the Prion Protein Is Required for Uptake of Prion Infectivity | 2.2 | 39 | Citations (PDF) |
| 419 | Anionic Phospholipid Interactions of the Prion Protein N Terminus Are Minimally Perturbing and Not Driven Solely by the Octapeptide Repeat Domain | 2.2 | 31 | Citations (PDF) |
| 420 | Residues Surrounding the Glycosylphosphatidylinositol Anchor Attachment Site of PrP Modulate Prion Infection: Insight from the Resistance of Rabbits to Prion Disease | 3.6 | 26 | Citations (PDF) |
| 421 | Larger temporal volume in elderly with high versus low beta-amyloid depositionBrain, 2010, 133, 3349-3358 | 8.4 | 148 | Citations (PDF) |
| 422 | Near-Infrared Fluorescence Imaging of Apoptotic Neuronal Cell Death in a Live Animal Model of Prion Disease | 3.7 | 26 | Citations (PDF) |
| 423 | Tau protein: Relevance to Parkinson's disease | 2.6 | 199 | Citations (PDF) |
| 424 | Pyroglutamate-Aβ: Role in the natural history of Alzheimer's disease | 2.6 | 75 | Citations (PDF) |
| 425 | BACE: Therapeutic target and potential biomarker for Alzheimer's disease | 2.6 | 61 | Citations (PDF) |
| 426 | Behavioural phenotype of APPC100.V717F transgenic mice over-expressing a mutant Aβ-bearing fragment is associated with reduced NMDA receptor density | 2.2 | 12 | Citations (PDF) |
| 427 | Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease | 33.6 | 662 | Citations (PDF) |
| 428 | Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging | 3.4 | 956 | Citations (PDF) |
| 429 | Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice | 0.7 | 27 | Citations (PDF) |
| 430 | Blood-Borne Amyloid-β Dimer Correlates with Clinical Markers of Alzheimer's Disease | 3.7 | 72 | Citations (PDF) |
| 431 | Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative | 0.5 | 64 | Citations (PDF) |
| 432 | Alzheimer's Aβ Peptides with Disease-Associated N-Terminal Modifications: Influence of Isomerisation, Truncation and Mutation on Cu2+ Coordination | 2.3 | 41 | Citations (PDF) |
| 433 | Pharmacotherapeutic targets in Alzheimer's disease | 4.0 | 51 | Citations (PDF) |
| 434 | Paradoxical Condensation of Copper with Elevated β-Amyloid in Lipid Rafts under Cellular Copper Deficiency Conditions | 2.2 | 58 | Citations (PDF) |
| 435 | The Caenorhabditis elegans Aβ1–42 Model of Alzheimer Disease Predominantly Expresses Aβ3–42 | 2.2 | 121 | Citations (PDF) |
| 436 | Regulation of Prion Gene Expression by Transcription Factors SP1 and Metal Transcription Factor-1 | 2.2 | 65 | Citations (PDF) |
| 437 | High Striatal Amyloid β-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types | 6.8 | 167 | Citations (PDF) |
| 438 | Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease clusterBrain, 2009, 132, 493-501 | 8.4 | 27 | Citations (PDF) |
| 439 | Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias | 5.1 | 107 | Citations (PDF) |
| 440 | Dominant roles of the polybasic proline motif and copper in the PrP23-89-mediated stress protection response | 2.4 | 41 | Citations (PDF) |
| 441 | Membrane‐targeted strategies for modulating APP and Aβ‐mediated toxicity | 4.0 | 4 | Citations (PDF) |
| 442 | Aβ aggregation and possible implications in Alzheimer's disease pathogenesis | 4.0 | 151 | Citations (PDF) |
| 443 | Stimulus pattern dependence of the Alzheimer's disease amyloid-β 42 peptide's inhibition of long term potentiation in mouse hippocampal slices | 2.5 | 34 | Citations (PDF) |
| 444 | Formation of dopamine-mediated α-synuclein-soluble oligomers requires methionine oxidation | 3.7 | 110 | Citations (PDF) |
| 445 | In vitro characterisation of BF227 binding to α-synuclein/Lewy bodies | 4.3 | 101 | Citations (PDF) |
| 446 | Dopamine D
2
receptor knockout mice develop features of Parkinson disease | 6.6 | 43 | Citations (PDF) |
| 447 | Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease | 1.8 | 143 | Citations (PDF) |
| 448 | Copper Coordination by Familial Mutants of Parkinson’s Disease-Associated α-Synuclein | 0.9 | 10 | Citations (PDF) |
| 449 | Chronic Exposure to High Levels of Zinc or Copper has Little Effect on Brain Metal Homeostasis or Aβ Accumulation in Transgenic APP-C100 Mice | 4.0 | 18 | Citations (PDF) |
| 450 | Amyloid Imaging in Alzheimer’s Disease and Other Dementias | 2.1 | 34 | Citations (PDF) |
| 451 | PrPC-related signal transduction is influenced by copper, membrane integrity and the alpha cleavage site | 12.4 | 40 | Citations (PDF) |
| 452 | Restored degradation of the Alzheimer’s amyloid‐β peptide by targeting amyloid formation | 3.8 | 88 | Citations (PDF) |
| 453 | Sustained Activation of Glial Cell Epidermal Growth Factor Receptor by Bis(thiosemicarbazonato) Metal Complexes Is Associated with Inhibition of Protein Tyrosine Phosphatase Activity | 5.6 | 39 | Citations (PDF) |
| 454 | Therapeutic interventions ameliorating prion disease | 3.8 | 15 | Citations (PDF) |
| 455 | Alanine-2 Carbonyl is an Oxygen Ligand in Cu2+ Coordination of Alzheimer’s Disease Amyloid-β Peptide − Relevance to N-Terminally Truncated Forms | 15.0 | 165 | Citations (PDF) |
| 456 | Pleomorphic Copper Coordination by Alzheimer’s Disease Amyloid-β Peptide | 15.0 | 239 | Citations (PDF) |
| 457 | Plasma Amyloid β42 and Amyloid β40 Levels Are Associated With Early Cognitive Dysfunction After Cardiac Surgery | 2.3 | 38 | Citations (PDF) |
| 458 | Increased Proportions of C1 Truncated Prion Protein Protect Against Cellular M1000 Prion Infection | 1.8 | 48 | Citations (PDF) |
| 459 | SAGE Analysis of Genes Differentially Expressed in Presymptomatic TgSOD1G93A Transgenic Mice Identified Cellular Processes Involved in Early Stage of ALS Pathology | 2.4 | 17 | Citations (PDF) |
| 460 | The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias | 3.7 | 96 | Citations (PDF) |
| 461 | The solubility of α-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease | 3.8 | 181 | Citations (PDF) |
| 462 | Exacerbation of Copper Toxicity in Primary Neuronal Cultures Depleted of Cellular Glutathione | 3.8 | 51 | Citations (PDF) |
| 463 | Identification of the Alzheimer's disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth | 4.9 | 53 | Citations (PDF) |
| 464 | Neurotoxicity from glutathione depletion is mediated by Cu-dependent p53 activation | 3.7 | 25 | Citations (PDF) |
| 465 | A manganese-superoxide dismutase/catalase mimetic extends survival in a mouse model of human prion disease | 3.7 | 54 | Citations (PDF) |
| 466 | Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism | 17.9 | 668 | Citations (PDF) |
| 467 | Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial | 17.9 | 716 | Citations (PDF) |
| 468 | Stabilization of Neurotoxic Soluble β-Sheet-Rich Conformations of the Alzheimer's Disease Amyloid-β Peptide | 2.2 | 92 | Citations (PDF) |
| 469 | The Structure of the Amyloid-β Peptide High-Affinity Copper II Binding Site in Alzheimer Disease | 2.2 | 119 | Citations (PDF) |
| 470 | Formation of a High Affinity Lipid-Binding Intermediate during the Early Aggregation Phase of α-Synuclein | 2.4 | 65 | Citations (PDF) |
| 471 | Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ | 11.0 | 676 | Citations (PDF) |
| 472 | Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease | 2.6 | 237 | Citations (PDF) |
| 473 | Clioquinol inhibits peroxide-mediated toxicity through up-regulation of phosphoinositol-3-kinase and inhibition of p53 activity | 2.6 | 26 | Citations (PDF) |
| 474 | Mouse-adapted sporadic human Creutzfeldt–Jakob disease prions propagate in cell culture | 2.6 | 63 | Citations (PDF) |
| 475 | α-Synuclein transgenic mice exhibit reduced anxiety-like behaviour | 4.0 | 67 | Citations (PDF) |
| 476 | Dimeric structures of α-synuclein bind preferentially to lipid membranes | 2.2 | 45 | Citations (PDF) |
| 477 | Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging | 4.4 | 81 | Citations (PDF) |
| 478 | Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers | 2.6 | 47 | Citations (PDF) |
| 479 | Automated 11C-PiB Standardized Uptake Value Ratio | 2.7 | 24 | Citations (PDF) |
| 480 | Amyloid-β Peptide (Aβ) Neurotoxicity Is Modulated by the Rate of Peptide Aggregation: Aβ Dimers and Trimers Correlate with Neurotoxicity | 3.7 | 205 | Citations (PDF) |
| 481 | Cu2+Binding Modes of Recombinant α-Synuclein − Insights from EPR Spectroscopy | 15.0 | 104 | Citations (PDF) |
| 482 | Inhibition of γ‐secretase causes increased secretion of amyloid precursor protein C‐terminal fragments in association with exosomes | 0.6 | 243 | Citations (PDF) |
| 483 | Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests | 7.8 | 235 | Citations (PDF) |
| 484 | In VitroCharacterization of Pittsburgh Compound-B Binding to Lewy Bodies | 3.7 | 162 | Citations (PDF) |
| 485 | -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's diseaseBrain, 2007, 130, 2837-2844 | 8.4 | 767 | Citations (PDF) |
| 486 | Evaluating Atypical Dementia Syndromes Using Positron Emission Tomography With Carbon 11–Labeled Pittsburgh Compound B | 6.8 | 74 | Citations (PDF) |
| 487 | Membrane interactions and the effect of metal ions of the amyloidogenic fragment Aβ(25–35) in comparison to Aβ(1–42) | 2.2 | 46 | Citations (PDF) |
| 488 | Cholesterol and Clioquinol modulation of Aβ(1–42) interaction with phospholipid bilayers and metals | 2.2 | 34 | Citations (PDF) |
| 489 | Plasma α-synuclein is decreased in subjects with Parkinson's disease | 4.0 | 155 | Citations (PDF) |
| 490 | 313: Imaging brain amyloid in ageing and dementia with C-11 PIB PET | 1.6 | 0 | Citations (PDF) |
| 491 | A primer of amyloid nomenclature | 4.6 | 326 | Citations (PDF) |
| 492 | Concentration Dependent Cu2+Induced Aggregation and Dityrosine Formation of the Alzheimer's Disease Amyloid-β Peptide† | 2.4 | 191 | Citations (PDF) |
| 493 | Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A amyloid pathwayBrain, 2006, 129, 2823-2839 | 8.4 | 148 | Citations (PDF) |
| 494 | Amyloid-β Peptide Disruption of Lipid Membranes and the Effect of Metal Ions | 4.1 | 162 | Citations (PDF) |
| 495 | Linker Histone H1 Binds to Disease Associated Amyloid-like Fibrils | 4.1 | 58 | Citations (PDF) |
| 496 | Decreased phosphatidylethanolamine binding protein expression correlates with Aβ accumulation in the Tg2576 mouse model of Alzheimer's disease | 3.4 | 72 | Citations (PDF) |
| 497 | Pathways to the discovery of the Aβ amyloid of Alzheimer's disease | 2.6 | 26 | Citations (PDF) |
| 498 | The beta-amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane | 3.8 | 34 | Citations (PDF) |
| 499 | Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics | 3.8 | 216 | Citations (PDF) |
| 500 | Copper-dependent inhibition of cytochrome c oxidase by A?1?42requires reduced methionine at residue 35 of the A? peptide | 3.8 | 42 | Citations (PDF) |
| 501 | Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn2+ complexes in Alzheimer's disease | 6.8 | 79 | Citations (PDF) |
| 502 | Overexpression of Aβ is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model | 6.8 | 41 | Citations (PDF) |
| 503 | Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: Implications for Alzheimer β-amyloid pathology | 3.0 | 97 | Citations (PDF) |
| 504 | Delineating common molecular mechanisms in Alzheimer's and prion diseases | 6.7 | 99 | Citations (PDF) |
| 505 | Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity | 2.2 | 284 | Citations (PDF) |
| 506 | Copper-mediated Amyloid-β Toxicity Is Associated with an Intermolecular Histidine Bridge | 2.2 | 180 | Citations (PDF) |
| 507 | C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1 | 2.9 | 139 | Citations (PDF) |
| 508 | Prion protein glycosylation | 3.8 | 77 | Citations (PDF) |
| 509 | In vitro gamma-secretase cleavage of the Alzheimer's amyloid precursor protein correlates to a subset of presenilin complexes and is inhibited by zinc | 5.4 | 49 | Citations (PDF) |
| 510 | Metals and amyloid‐β in Alzheimer's disease | 1.8 | 331 | Citations (PDF) |
| 511 | Extended period of asymptomatic prion disease after low dose inoculation: Assessment of detection methods and implications for infection control | 5.1 | 20 | Citations (PDF) |
| 512 | The preparation of123/125I-clioquinol for the study of Aβ protein in Alzheimer's disease | 0.8 | 12 | Citations (PDF) |
| 513 | Crystallization and preliminary crystallographic studies of the copper-binding domain of the amyloid precursor protein of Alzheimer's disease | 0.7 | 9 | Citations (PDF) |
| 514 | Methionine regulates copper/hydrogen peroxide oxidation products of Aβ | 2.0 | 93 | Citations (PDF) |
| 515 | Amyloid: Toward terminology clarification Report from the Nomenclature Committee of the International Society of Amyloidosis | 4.6 | 325 | Citations (PDF) |
| 516 | Dopamine promotes α‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathway | 0.6 | 253 | Citations (PDF) |
| 517 | The Amyloid Precursor Protein (APP) of Alzheimer Disease and Its Paralog, APLP2, Modulate the Cu/Zn-Nitric Oxide-catalyzed Degradation of Glypican-1 Heparan Sulfate in Vivo | 2.2 | 49 | Citations (PDF) |
| 518 | Transition-State Analogue γ-Secretase Inhibitors Stabilize a 900 kDa Presenilin/Nicastrin Complex† | 2.4 | 45 | Citations (PDF) |
| 519 | Lyodura use and the risk of iatrogenic Creutzfeldt–Jakob disease in Australia | 1.7 | 33 | Citations (PDF) |
| 520 | Enhanced Toxicity and Cellular Binding of a Modified Amyloid β Peptide with a Methionine to Valine Substitution | 2.2 | 99 | Citations (PDF) |
| 521 | Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease β‐amyloid | 0.6 | 257 | Citations (PDF) |
| 522 | The Proteolytic Processing of the Amyloid Precursor Protein Gene Family Members APLP-1 and APLP-2 Involves α-, β-, γ-, and ϵ-Like Cleavages | 2.2 | 193 | Citations (PDF) |
| 523 | Nicastrin expression in mouse peripheral tissues is not co-ordinated with presenilin and is high in muscle | 3.8 | 16 | Citations (PDF) |
| 524 | Gene knockout of amyloid precursor protein and amyloid precursor‐like protein‐2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts | 3.8 | 102 | Citations (PDF) |
| 525 | Neurodegenerative diseases and oxidative stress | 79.7 | 3,301 | Citations (PDF) |
| 526 | Iron inhibits neurotoxicity induced by trace copper and biological reductants | 2.5 | 45 | Citations (PDF) |
| 527 | Brain ?-Amyloid Accumulation in Transgenic Mice Expressing Mutant Superoxide Dismutase 1 | 3.4 | 14 | Citations (PDF) |
| 528 | Characterizing bathocuproine self-association and subsequent binding to Alzheimer's disease amyloidβ-peptide by NMR | 2.0 | 25 | Citations (PDF) |
| 529 | Characterization of presenilin complexes from mouse and human brain using Blue Native gel electrophoresis reveals high expression in embryonic brain and minimal change in complex mobility with pathogenic presenilin mutations | 0.2 | 22 | Citations (PDF) |
| 530 | Increased β‐Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects | 6.6 | 95 | Citations (PDF) |
| 531 | Metal-protein attenuating compounds and Alzheimer’s disease | 3.9 | 62 | Citations (PDF) |
| 532 | APP intracellular domain is increased and soluble Aβ is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease | 5.1 | 82 | Citations (PDF) |
| 533 | Interaction of the Molecular Chaperone αB-Crystallin with α-Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity | 4.1 | 214 | Citations (PDF) |
| 534 | Transmissible spongiform encephalopathies | 62.1 | 266 | Citations (PDF) |
| 535 | Copper Modulation of Ion Channels of PrP[106–126] Mutant Prion Peptide Fragments | 2.5 | 31 | Citations (PDF) |
| 536 | Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease ?-amyloid protein precursor: Effect of C-terminal truncation on production of ?-amyloid protein | 3.1 | 68 | Citations (PDF) |
| 537 | Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets | 3.1 | 155 | Citations (PDF) |
| 538 | Selecting cells with different Alzheimer's disease gamma-secretase activity using FACS. Differential effect of presenilin exon 9 deletion on gamma- and epsilon-cleavage | 0.2 | 6 | Citations (PDF) |
| 539 | In Vitro Characterization of the Presenilin-Dependent γ-Secretase Complex Using a Novel Affinity Ligand | 2.4 | 83 | Citations (PDF) |
| 540 | Methionine oxidation: Implications for the mechanism of toxicity of the β-amyloid peptide from Alzheimer's disease | 2.1 | 7 | Citations (PDF) |
| 541 | Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease | 62.1 | 353 | Citations (PDF) |
| 542 | The Transmembrane Domain of the Amyloid Precursor Protein in Microsomal Membranes Is on Both Sides Shorter than Predicted | 2.2 | 49 | Citations (PDF) |
| 543 | Metal Ions, pH, and Cholesterol Regulate the Interactions of Alzheimer's Disease Amyloid-β Peptide with Membrane Lipid | 2.2 | 196 | Citations (PDF) |
| 544 | Neurotoxic, Redox-competent Alzheimer's β-Amyloid Is Released from Lipid Membrane by Methionine Oxidation | 2.2 | 182 | Citations (PDF) |
| 545 | Spectrum of Saccade System Function in Alzheimer Disease | 6.8 | 81 | Citations (PDF) |
| 546 | Cu2+-induced modification of the kinetics of Aβ(1-42) channels | 4.2 | 20 | Citations (PDF) |
| 547 | Overexpression of Alzheimer's Disease Amyloid-β Opposes the Age-dependent Elevations of Brain Copper and Iron | 2.2 | 337 | Citations (PDF) |
| 548 | Metalloenzyme-like Activity of Alzheimer's Disease β-Amyloid | 2.2 | 555 | Citations (PDF) |
| 549 | Platelet α- and γ-synucleins in Parkinson's disease and normal control subjects | 2.6 | 49 | Citations (PDF) |
| 550 | Oligodendrocytes from neural stem cells express ??-synuclein: increased numbers from presenilin 1 deficient mice | 1.5 | 20 | Citations (PDF) |
| 551 | Mechanisms of peripheral microvascular dysfunction in transgenic mice overexpressing the Alzheimer's disease amyloid Aβ protein | 2.6 | 23 | Citations (PDF) |
| 552 | A Novel ε-Cleavage within the Transmembrane Domain of the Alzheimer Amyloid Precursor Protein Demonstrates Homology with Notch Processing | 2.4 | 346 | Citations (PDF) |
| 553 | The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain | 7.5 | 71 | Citations (PDF) |
| 554 | Contrasting, Species-Dependent Modulation of Copper-Mediated Neurotoxicity by the Alzheimer's Disease Amyloid Precursor Protein | 3.7 | 85 | Citations (PDF) |
| 555 | Alzheimer’s disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF) | 2.5 | 17 | Citations (PDF) |
| 556 | Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease | 6.6 | 563 | Citations (PDF) |
| 557 | Creutzfeldt-Jakob disease cluster in an Australian rural city | 6.6 | 24 | Citations (PDF) |
| 558 | Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model | 6.6 | 164 | Citations (PDF) |
| 559 | Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition | 3.8 | 42 | Citations (PDF) |
| 560 | Generation of a recombinant Fab antibody reactive with the Alzheimer's disease-related Aβpeptide | 3.3 | 23 | Citations (PDF) |
| 561 | Intracellular Accumulation of Detergent-Soluble Amyloidogenic Aβ Fragment of Alzheimer's Disease Precursor Protein in the Hippocampus of Aged Transgenic Mice | 3.8 | 72 | Citations (PDF) |
| 562 | Toxicity of substrate-bound amyloid peptides on vascular smooth muscle cells is enhanced by homocysteine | 0.2 | 39 | Citations (PDF) |
| 563 | Sublethal Concentrations of Prion Peptide PrP106–126 or the Amyloid Beta Peptide of Alzheimer's Disease Activates Expression of Proapoptotic Markers in Primary Cortical Neurons | 5.1 | 68 | Citations (PDF) |
| 564 | Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice | 11.0 | 1,502 | Citations (PDF) |
| 565 | Alzheimer's Disease Amyloid-β Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits | 2.2 | 626 | Citations (PDF) |
| 566 | Aspartyl Protease Inhibitor Pepstatin Binds to the Presenilins of Alzheimer's Disease† | 2.4 | 44 | Citations (PDF) |
| 567 | Henryk M. Wisniewski and the amyloid theory of Alzheimer's disease | 2.6 | 4 | Citations (PDF) |
| 568 | The Worster-Drought Syndrome and Other Syndromes of Dementia With Spastic Paraparesis: The Paradox of Molecular Pathology | 1.8 | 7 | Citations (PDF) |
| 569 | Amyloid Aβ levels in Alzheimer's disease – A diagnostic tool and the key to understanding the natural history of Aβ? | 2.6 | 12 | Citations (PDF) |
| 570 | Identification of structural variations in the carboxyl terminus of Alzheimer's disease-associatedβA4[1-42] amyloid using a monoclonal antibody | 3.3 | 3 | Citations (PDF) |
| 571 | Homocysteine potentiates copper‐ and amyloid beta peptide‐mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's‐type neurodegenerative pathways | 3.8 | 235 | Citations (PDF) |
| 572 | Interaction of linear homologous DNA duplexes via Holliday junction formation | 0.2 | 18 | Citations (PDF) |
| 573 | The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from γ-secretase | 0.2 | 118 | Citations (PDF) |
| 574 | Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126 | 3.1 | 48 | Citations (PDF) |
| 575 | Variable phenotype of Alzheimer's disease with spastic paraparesis | 6.6 | 97 | Citations (PDF) |
| 576 | Pharmacological Knock-down of the Presenilin 1 Heterodimer by a Novel γ-Secretase Inhibitor | 2.2 | 77 | Citations (PDF) |
| 577 | Novel Prion Protein Gene Mutation in an Octogenarian With Creutzfeldt-Jakob Disease | 6.8 | 53 | Citations (PDF) |
| 578 | Presenilin 1 expression in yeast lowers secretion of the amyloid precursor protein | 1.5 | 5 | Citations (PDF) |
| 579 | A? peptides and calcium influence secretion of the amyloid protein precursor from chick sympathetic neurons in culture | 3.1 | 12 | Citations (PDF) |
| 580 | Amyloidogenicity and neurotoxicity of peptides corresponding to the helical regions of PrPC | 3.1 | 53 | Citations (PDF) |
| 581 | Novel Leu723Pro amyloid precursor protein mutation increases amyloid ?42(43) peptide levels and induces apoptosis | 6.6 | 89 | Citations (PDF) |
| 582 | Substrate‐Bound β‐Amyloid Peptides Inhibit Cell Adhesion and Neurite Outgrowth in Primary Neuronal Cultures | 3.8 | 50 | Citations (PDF) |
| 583 | Alzheimer Disease | 6.8 | 53 | Citations (PDF) |
| 584 | Identification of cis-Elements Regulating Exon 15 Splicing of the Amyloid Precursor Protein Pre-mRNA | 2.2 | 9 | Citations (PDF) |
| 585 | Genomic Neurology | 6.8 | 0 | Citations (PDF) |
| 586 | Prospects for Pharmacological Intervention in Alzheimer Disease | 6.8 | 138 | Citations (PDF) |
| 587 | Accumulation of Insoluble α-Synuclein in Dementia with Lewy Bodies | 5.1 | 78 | Citations (PDF) |
| 588 | What the evolution of the amyloid protein precursor supergene family tells us about its function | 3.5 | 195 | Citations (PDF) |
| 589 | Correct heteroduplex formation for mutation detection analysis | 0.4 | 0 | Citations (PDF) |
| 590 | Correct Heteroduplex Formation for Mutation Detection Analysis | 0.4 | 13 | Citations (PDF) |
| 591 | The Alzheimer's Disease Amyloid Precursor Protein Modulates Copper-Induced Toxicity and Oxidative Stress in Primary Neuronal Cultures | 3.7 | 220 | Citations (PDF) |
| 592 | Proteolytic Processing of the Alzheimer's Disease Amyloid Precursor Protein within Its Cytoplasmic Domain by Caspase-like Proteases | 2.2 | 159 | Citations (PDF) |
| 593 | Mechanism of the cleavage specificity of Alzheimer’s disease γ-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein | 7.5 | 245 | Citations (PDF) |
| 594 | Amyloid precursor protein of Alzheimer's disease: evidence for a stable, full-length, trans-membrane pool in primary neuronal cultures | 3.5 | 25 | Citations (PDF) |
| 595 | The amyloid β‐protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain‐sensitive trypsin‐like serine protease in cultures of chick sympathetic neurons | 0.2 | 17 | Citations (PDF) |
| 596 | Title is missing! | 11.0 | 233 | Citations (PDF) |
| 597 | It all sticks together—the APP-related family of proteins and Alzheimer's disease | 7.8 | 105 | Citations (PDF) |
| 598 | Title is missing! | 0.3 | 0 | Citations (PDF) |
| 599 | The synthesis and spectroscopic analysis of the neurotoxic prion peptide 106–126: Comparative use of manual Boc and Fmoc chemistry | 0.3 | 11 | Citations (PDF) |
| 600 | Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice | 2.5 | 289 | Citations (PDF) |
| 601 | Mitochondrial respiratory chain activity in the human brain as a function of age | 4.7 | 171 | Citations (PDF) |
| 602 | Irregular distribution of cytochromec oxidase protein subunits in aging and Alzheimer's disease | 6.6 | 59 | Citations (PDF) |
| 603 | Soluble pool of A? amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease | 6.6 | 1,782 | Citations (PDF) |
| 604 | Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies | 3.1 | 21 | Citations (PDF) |
| 605 | Aqueous Dissolution of Alzheimer's Disease Aβ Amyloid Deposits by Biometal Depletion | 2.2 | 467 | Citations (PDF) |
| 606 | α-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease β-amyloid plaque cores | 1.9 | 92 | Citations (PDF) |
| 607 | Recombinant human amyloid precursor-like protein 2 (APLP2) expressed in the yeastPichia pastoriscan stimulate neurite outgrowth | 2.7 | 59 | Citations (PDF) |
| 608 | A novel substrate for analyzing Alzheimer's disease γ-secretase | 2.7 | 47 | Citations (PDF) |
| 609 | Familial Prion Disease Mutation Alters the Secondary Structure of Recombinant Mouse Prion Protein: Implications for the Mechanism of Prion Formation† | 2.4 | 35 | Citations (PDF) |
| 610 | Non-Aβ Component of Alzheimer's Disease Amyloid (NAC) Revisited | 3.4 | 193 | Citations (PDF) |
| 611 | Prion Protein-Deficient Neurons Reveal Lower Glutathione Reductase Activity and Increased Susceptibility to Hydrogen Peroxide Toxicity | 3.4 | 188 | Citations (PDF) |
| 612 | Copper inhibits
β
-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion | 3.8 | 161 | Citations (PDF) |
| 613 | The amyloid precursor protein of Alzheimer disease in human brain and blood | 2.9 | 76 | Citations (PDF) |
| 614 | Early-onset Alzheimerʼs disease caused by a novel mutation at codon 219 of the presenilin-1 gene | 1.5 | 22 | Citations (PDF) |
| 615 | Neurite-Outgrowth Regulating Functions of the Amyloid Protein Precursor of Alzheimer's Disease | 2.6 | 60 | Citations (PDF) |
| 616 | Proteolytic Fragments of Alzheimer’s Disease‐Associated Presenilin 1 Are Present in Synaptic Organelles and Growth Cone Membranes of Rat Brain | 3.8 | 56 | Citations (PDF) |
| 617 | Inhibition of platelet activation by the Alzheimer's disease amyloid precursor protein | 2.7 | 32 | Citations (PDF) |
| 618 | Effects of the amyloid protein precursor of Alzheimer's disease and other ligands of the LDL receptor-related protein on neurite outgrowth from sympathetic neurons in culture | 2.7 | 28 | Citations (PDF) |
| 619 | Subcellular localization of the Alzheimer's disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system | 4.6 | 13 | Citations (PDF) |
| 620 | Copper-Binding Amyloid Precursor Protein Undergoes a Site-Specific Fragmentation in the Reduction of Hydrogen Peroxide† | 2.4 | 132 | Citations (PDF) |
| 621 | Products of the Alzheimer's disease amyloid precursor protein generated by,β-secretase are present in human platelets, and secreted upon degranulation 1998, 13, 236-244 | | 13 | Citations (PDF) |
| 622 | Science, medicine, and the future: Alzheimer's disease | 0.1 | 88 | Citations (PDF) |
| 623 | Transgenic
Drosophila
expressing human amyloid precursor protein show γ-secretase activity and a blistered-wing phenotype | 7.5 | 153 | Citations (PDF) |
| 624 | Survival of Cultured Neurons from Amyloid Precursor Protein Knock-Out Mice against Alzheimer’s Amyloid-β Toxicity and Oxidative Stress | 3.7 | 93 | Citations (PDF) |
| 625 | Acetylcholinesterase Is Increased in the Brains of Transgenic Mice Expressing the C‐Terminal Fragment (CT100) of the β‐Amyloid Protein Precursor of Alzheimer's Disease | 3.8 | 97 | Citations (PDF) |
| 626 | Mutations in the Transmembrane Domain of APP Altering γ-Secretase Specificity† | 2.4 | 104 | Citations (PDF) |
| 627 | A Novel Metalloprotease in Rat Brain Cleaves the Amyloid Precursor Protein of Alzheimer's Disease Generating Amyloidogenic Fragments | 2.4 | 23 | Citations (PDF) |
| 628 | Expression of Human Amyloid Precursor Protein Ectodomains inPichia pastoris:Analysis of Culture Conditions, Purification, and Characterization | 1.2 | 56 | Citations (PDF) |
| 629 | Expression and analysis of heparin-binding regions of the amyloid precursor protein of Alzheimer's disease | 2.7 | 49 | Citations (PDF) |
| 630 | Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease | 62.1 | 39 | Citations (PDF) |
| 631 | Commentary on the Consensus Recommendations for the Post Mortem Diagnosis of Alzheimer’s Disease | 3.4 | 5 | Citations (PDF) |
| 632 | Intracellular and secreted Alzheimer -amyloid species are generated by distinct mechanisms in cultured hippocampal neurons | 7.5 | 153 | Citations (PDF) |
| 633 | Formation of stable complexes between two Alzheimer's disease gene products: Presenilin-2 and β-amyloid precursor protein | 33.0 | 239 | Citations (PDF) |
| 634 | Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides | 33.0 | 737 | Citations (PDF) |
| 635 | Clues to the Etiology of Alzheimer's Disease Through the Study of the Amyloid Precursor Protein | 5.0 | 0 | Citations (PDF) |
| 636 | Human Amyloid Precursor‐Like Protein 1 | 0.2 | 55 | Citations (PDF) |
| 637 | Down-regulation of the amyloid protein precursor of Alzheimer's disease by antisense oligonucleotides reduces neuronal adhesion to specific substrata | 2.5 | 50 | Citations (PDF) |
| 638 | Collection and normal levels of the amyloid precursor protein in plasma | 6.6 | 21 | Citations (PDF) |
| 639 | Alzheimer's disease-associated presenilin 1 in neuronal cells: Evidence for localization to the endoplasmic reticulum-Golgi intermediate compartment 1997, 49, 719-731 | | 73 | Citations (PDF) |
| 640 | Identification of Heparin‐Binding Domains in the Amyloid Precursor Protein of Alzheimer's Disease by Deletion Mutagenesis and Peptide Mapping | 3.8 | 74 | Citations (PDF) |
| 641 | The Amyloid β‐Protein of Alzheimer's Disease Increases Acetylcholinesterase Expression by Increasing Intracellular Calcium in Embryonal Carcinoma P19 Cells | 3.8 | 116 | Citations (PDF) |
| 642 | Regulation of APP Expression, Biogenesis and Metabolism by Extracellular Matrix and Cytokinesa | 4.0 | 22 | Citations (PDF) |
| 643 | APP Gene Family Alternative Splicing Generates Functionally Related Isoformsa | 4.0 | 100 | Citations (PDF) |
| 644 | The Role of Heparan Sulfate Proteoglycans in the Pathogenesis of Alzheimer's Diseasea | 4.0 | 32 | Citations (PDF) |
| 645 | Rapid cellular uptake of Alzheimer amyloid βA4 peptide by cultured human neuroblastoma cells | 2.7 | 48 | Citations (PDF) |
| 646 | 329 Multiple amyloidogenic pathways — where is the therapeutic target? | 3.4 | 0 | Citations (PDF) |
| 647 | Emergence of a new variant of Creutzfeldt-Jakob disease in Europe? | 1.6 | 1 | Citations (PDF) |
| 648 | Iatrogenic and zoonotic Creutzfeldt–Jakob disease: the Australian perspective | 1.7 | 21 | Citations (PDF) |
| 649 | In reply | 1.7 | 0 | Citations (PDF) |
| 650 | Amyloid, aluminium and the aetiology of Alzheimer's disease | 1.7 | 1 | Citations (PDF) |
| 651 | Alzheimer's disease amyloid precursor protein on the surface of cortical neurons in primary culture co-localizes with adhesion patch components | 2.5 | 74 | Citations (PDF) |
| 652 | The amyloid precursor protein of Alzheimer's disease is found on the surface of static but not actively motile portions of neurites | 2.5 | 52 | Citations (PDF) |
| 653 | Missense mutations of thePS-1/S182gene in german early-onset Alzheimer's disease patients | 6.6 | 45 | Citations (PDF) |
| 654 | Regulation of Amyloid Protein Precursor (APP) Binding to Collagen and Mapping of the Binding Sites on APP and Collagen Type I | 2.2 | 146 | Citations (PDF) |
| 655 | Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay | 2.2 | 465 | Citations (PDF) |
| 656 | Secreted Glypican Binds to the Amyloid Precursor Protein of Alzheimer's Disease (APP) and Inhibits APP-induced Neurite Outgrowth | 2.2 | 87 | Citations (PDF) |
| 657 | The Nosology of Creutzfeldt‐Jakob Disease and Conditions Related to the Accumulation of PrPCJD in the Nervous System | 5.0 | 84 | Citations (PDF) |
| 658 | Characterization of the high affinity heparin binding site of the Alzheimer's disease βA4 amyloid precursor protein (APP) and its enhancement by zinc(II) | 3.0 | 57 | Citations (PDF) |
| 659 | A synthetic substrate assay for the gamma-secretase of the β-A4 amyloid of alzheimer's disease | 2.0 | 2 | Citations (PDF) |
| 660 | Amyloid, aluminium and the aetiology of Alzheimer's disease | 1.7 | 29 | Citations (PDF) |
| 661 | Extracellular Matrix Influences the Biogenesis of Amyloid Precursor Protein in Microglial Cells | 2.2 | 68 | Citations (PDF) |
| 662 | Proteolytic Processing of Alzheimer's Disease βA4 Amyloid Precursor Protein in Human Platelets | 2.2 | 107 | Citations (PDF) |
| 663 | Intracellular Production of .beta.A4 Amyloid of Alzheimer's Disease: Modulation by Phosphoramidon and Lack of Coupling to the Secretion of the Amyloid Precursor Protein | 2.4 | 105 | Citations (PDF) |
| 664 | Candidate .gamma.-Secretases in the Generation of the Carboxyl Terminus of the Alzheimer's Disease .beta.A4 Amyloid: Possible Involvement of Cathepsin D | 2.4 | 101 | Citations (PDF) |
| 665 | Expression of the Amyloid Precursor Protein of Alzheimer's Disease on the Surface of Transfected HeLa Cells | 3.1 | 14 | Citations (PDF) |
| 666 | Cells from Peripheral Tissues that Exhibit High APP Expression are Characterized by their High Membrane Fusion Activity | 1.8 | 24 | Citations (PDF) |
| 667 | Gelatinase A possesses a β-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease | 2.7 | 43 | Citations (PDF) |
| 668 | Expression of the amyloid protein precursor of Alzheimer's disease in the developing rat olfactory system | 2.1 | 51 | Citations (PDF) |
| 669 | Affinity Purification of Proteoglycans that Bind to the Amyloid Protein Precursor of Alzheimer's Disease | 3.8 | 32 | Citations (PDF) |
| 670 | Alzheimer's disease amyloid precursor protein (ApPP): proteolytic processing, secretases and βA4 amyloid production | 4.6 | 46 | Citations (PDF) |
| 671 | Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants | 3.1 | 67 | Citations (PDF) |
| 672 | Comparison of clinical state, retrospective informant interview and the neuropathologic diagnosis of alzheimer's disease | 2.2 | 33 | Citations (PDF) |
| 673 | Complete nucleotide and deduced amino acid sequence of rat amyloid protein precusor-like protein 2 () | 3.4 | 31 | Citations (PDF) |
| 674 | APP gene family: unique age-associated changes in splicing of Alzheimer's βA4-amyloid protein precursor | 5.1 | 54 | Citations (PDF) |
| 675 | The βA4 amyloid precursor protein binding to copper | 2.7 | 236 | Citations (PDF) |
| 676 | Interaction between the zinc(II) and the heparin binding site of the Alzheimer's disease βA4 amyloid precursor protein (APP) | 2.7 | 88 | Citations (PDF) |
| 677 | Transforming growth factor β mediates increase of mature transmembrane amyloid precursor protein in microglial cells | 2.7 | 47 | Citations (PDF) |
| 678 | The metabolism of the βA4 amyloid precursor protein in Alzheimer's disease | 3.4 | 0 | Citations (PDF) |
| 679 | Alzheimer's disease: a clearer definition of the genetic components | 1.7 | 6 | Citations (PDF) |
| 680 | Amyloidogenicity of rodent and human βA4 sequences | 2.7 | 154 | Citations (PDF) |
| 681 | Regulation and Expression of the Alzheimer's β/A4 Amyloid Protein Precursor in Health, Disease, and Down's Syndromea | 4.0 | 111 | Citations (PDF) |
| 682 | The Role of Extracellular Matrix in the Processing of the Amyloid Protein Precursor of Alzheimer's Diseasea | 4.0 | 16 | Citations (PDF) |
| 683 | The βA4 Amyloid Protein Precursor in Human Circulationa | 4.0 | 15 | Citations (PDF) |
| 684 | Expression of L-APP mRNA in Brain Cellsa | 4.0 | 17 | Citations (PDF) |
| 685 | Amyloid Precursor Protein (APP) in the Striatum in Alzheimerʼs Disease: An Immunohistochemical Study | 1.8 | 39 | Citations (PDF) |
| 686 | Amyloid-like properties of peptides flanking the epitope of amyloid precursor protein-specific monoclonal antibody 22C11. | 2.2 | 125 | Citations (PDF) |
| 687 | The expression of the amyloid precursor protein (APP) is regulated by two GC-elements in the promoter | 15.5 | 95 | Citations (PDF) |
| 688 | The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth | 11.0 | 461 | Citations (PDF) |
| 689 | β A4 amyloid protein and its precursor in Alzheimer's disease 1992, 56, 97-117 | | 33 | Citations (PDF) |
| 690 | Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides | 4.1 | 424 | Citations (PDF) |
| 691 | Human Brain ?A4 Amyloid Protein Precursor of Alzheimer's Disease: Purification and Partial Characterization | 3.8 | 53 | Citations (PDF) |
| 692 | Specific binding of the alzheimer βA4 amyloid precursor to collagen, laminin, and heparin | 1.3 | 22 | Citations (PDF) |
| 693 | An abnormality of plasma amyloid protein precursor in Alzheimer's disease | 6.6 | 56 | Citations (PDF) |
| 694 | Human and rodent sequence analogs of Alzheimer's amyloid betaA4 share similar properties and can be solubilized in buffers of pH 7.4 | 0.2 | 74 | Citations (PDF) |
| 695 | Quantitative changes in the amyloid βA4 precursor protein in Alzheimer cerebrospinal fluid | 1.9 | 62 | Citations (PDF) |
| 696 | Alternative splicing of the βA4 amyloid gene of Alzheimer's disease in cortex of control and Alzheimer's disease patients | 2.6 | 70 | Citations (PDF) |
| 697 | In-vitro matured human macrophages express Alzheimer's βA4-amyloid precursor protein indicating synthesis in microglial cells | 2.7 | 55 | Citations (PDF) |
| 698 | Localization of Alzheimer βA4 amyloid precursor protein at central and peripheral synaptic sites | 2.5 | 274 | Citations (PDF) |
| 699 | Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease | 4.1 | 596 | Citations (PDF) |
| 700 | Transplants of mouse trisomy 16 hippocampus provide a model of Alzheimer's disease neuropathology. | 7.3 | 58 | Citations (PDF) |
| 701 | Alzheimer's Disease: Molecular Basis of Structural Lesions | 5.0 | 10 | Citations (PDF) |
| 702 | The molecular pathology of amyloid deposition in Alzheimer's disease | 3.7 | 24 | Citations (PDF) |
| 703 | Amyloid Precursor Protein (APP) and ΒZA4 Amyloid in the Etiology of Alzheimer's Disease: Precursor‐Product Relationships in the Derangement of Neuronal Function | 5.0 | 211 | Citations (PDF) |
| 704 | Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. | 7.5 | 688 | Citations (PDF) |
| 705 | Entry of Neurotropic Arboviruses into the Central Nervous System: An In Vitro Study Using Mouse Brain Endothelium | 3.7 | 76 | Citations (PDF) |
| 706 | Processing of precursors of amyloid A4 protein in Alzheimer's disease | 3.4 | 0 | Citations (PDF) |
| 707 | Induced neuronal expression and alternative splicing pattern of the amyloid gene of Alzheimer's disease | 3.4 | 0 | Citations (PDF) |
| 708 | Nomenclature of amyloid A4 proteins and their precursors in Alzheimer's disease and down's syndrome | 3.4 | 16 | Citations (PDF) |
| 709 | Alzheimer protein precursors: Tyrosine phosphorylation of the cytoplasmic domain | 3.4 | 0 | Citations (PDF) |
| 710 | The βA4 amyloid protein and its precursors as biological markers for Alzheimer's disease | 3.4 | 0 | Citations (PDF) |
| 711 | Retinoic acid induced differentiated neuroblastoma cells show increased expression of the βA4 amyloid gene of Alzheimer's disease and an altered splicing pattern | 2.7 | 104 | Citations (PDF) |
| 712 | Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease | 34.5 | 671 | Citations (PDF) |
| 713 | The Pathology of the Amyloid A4 Precursor of Alzheimer's Disease | 3.8 | 10 | Citations (PDF) |
| 714 | AN ANALYSIS OF THE MORPHOLOGY OF SENILE PLAQUES IN DOWN'S SYNDROME PATIENTS OF DIFFERENT AGES USING IMMUNOCYTOCHEMICAL AND LECTIN HISTOCHEMICAL TECHNIQUES | 3.1 | 73 | Citations (PDF) |
| 715 | A4 amyloid protein immunoreactivity is present in Alzheimer's disease neurofibrillary tangles | 1.9 | 70 | Citations (PDF) |
| 716 | Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein | 33.6 | 1,268 | Citations (PDF) |
| 717 | A4 Protein in Alzheimer's Disease: Primary and Secondary Cellular Events in Extracellular Amyloid Deposition | 1.8 | 236 | Citations (PDF) |
| 718 | CREUTZFELDT-JAKOB DISEASE | 1.3 | 11 | Citations (PDF) |
| 719 | Rett syndrome: Abnormal membrane-bound lamellated inclusions in neurons and oligodendroglia | 0.5 | 25 | Citations (PDF) |
| 720 | The blood-brain barrier in Alzheimer's disease and normal aging | 3.4 | 20 | Citations (PDF) |
| 721 | PROMOTER OF ALZHEIMER??S DISEASE AMYLOID A4 PRECURSOR GENE | 1.3 | 1 | Citations (PDF) |
| 722 | AMYLOIDOGENICITY OF ALZHEIMER??S DISEASE-SPECIFIC AMYLOID A4 PROTEIN | 1.3 | 0 | Citations (PDF) |
| 723 | MOLECULAR PATHOLOGY OF THE AMYLOID A4 PRECURSOR OF ALZHEIMER??S DISEASE | 1.3 | 2 | Citations (PDF) |
| 724 | ALZHEIMER??S DISEASE AND THE AMYLOID GENE | 1.3 | 1 | Citations (PDF) |
| 725 | ALZHEIMER??S DISEASE AMYLOID A4 PRECURSOR GENE PRODUCTS | 1.3 | 1 | Citations (PDF) |
| 726 | Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease. | 7.3 | 358 | Citations (PDF) |
| 727 | Localization of the putative precursor of Alzheimer's disease-specific amyloid at nuclear envelopes of adult human muscle. | 7.3 | 69 | Citations (PDF) |
| 728 | The promoter of Alzheimer's disease amyloid A4 precursor gene. | 7.3 | 293 | Citations (PDF) |
| 729 | A4 amyloid protein deposition and the diagnosis of Alzheimer's disease | 1.0 | 347 | Citations (PDF) |
| 730 | AMYLOIDOGENIC PROTEIN PRECURSORS IN ALZHEIMERʼS DISEASE AND UNCONVENTIONAL VIRUS DISEASES | 1.8 | 0 | Citations (PDF) |
| 731 | Amyloid of neurofibrillary tangles of Guamanian parkinsonism-dementia and Alzheimer disease share identical amino acid sequence. | 7.5 | 94 | Citations (PDF) |
| 732 | Culture of mouse brain capillary endothelial cell lines that express factor VIII, γ-glutamyl transpeptidase, and form junctional complexes in vitro | 0.8 | 27 | Citations (PDF) |
| 733 | The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor | 37.9 | 4,703 | Citations (PDF) |
| 734 | Disordered innervation of cerebral vasculature as a cause of alzheimer's disease plaques and tangles | 3.4 | 2 | Citations (PDF) |
| 735 | Amyloid proteins in Alzheimer's disease | 3.4 | 1 | Citations (PDF) |
| 736 | DECONTAMINATION OF FORMALDEHYDE-FIXED TISSUES OF CREUTZFELDT-JAKOB DISEASE | 1.8 | 9 | Citations (PDF) |
| 737 | Regulation of liver and brain hexose monophosphate dehydrogenases by insulin and dietary intake in the female rat | 3.1 | 6 | Citations (PDF) |
| 738 | Increased Cerebral Glucose-6-Phosphate Dehydrogenase Activity in Alzheimer's Disease May Reflect Oxidative Stress | 3.8 | 234 | Citations (PDF) |
| 739 | AMYLOID PLAQUE CORE PROTEIN IN ALZHEIMERʼS DISEASE AND AGED DOWNʼS SYNDROME | 1.8 | 3 | Citations (PDF) |
| 740 | Amyloid plaque core protein in Alzheimer disease and Down syndrome. | 7.5 | 4,288 | Citations (PDF) |
| 741 | LETTER TO THE EDITOR | 1.8 | 11 | Citations (PDF) |
| 742 | Regulation of the multiple molecular forms of rat liver glucose 6-phospnate dehydrogenase by insulin and dietary restriction | 2.1 | 33 | Citations (PDF) |
| 743 | Loop arrays in mouse brain demonstrated with antisera to cytokeratins and monoclonal antibodies to several classes of intermediate filaments: Strain differences and developmental expression | 2.5 | 9 | Citations (PDF) |
| 744 | Etiology and pathogenesis of alzheimer's disease | 1.6 | 6 | Citations (PDF) |
| 745 | The Sequential Development of Spongiform Change and Gliosis of Scrapie in the Golden Syrian Hamster | 1.8 | 27 | Citations (PDF) |
| 746 | Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques | 9.1 | 181 | Citations (PDF) |
| 747 | A clinico-pathological study of a case of kuru | 2.1 | 17 | Citations (PDF) |
| 748 | Creutzfeldt-Jakob disease in an adolescent | 2.1 | 36 | Citations (PDF) |
| 749 | Monoclonal antibodies to central nervous system antigens | 2.3 | 28 | Citations (PDF) |
| 750 | THE FAMILIAL OCCURRENCE OF CREUTZFELDT-JAKOB DISEASE AND ALZHEIMER'S DISEASEBrain, 1981, 104, 535-558 | 8.4 | 257 | Citations (PDF) |
| 751 | Transmissible Spongiform Encephalopathy (Creutzfeldt-Jakob Disease) | 6.8 | 64 | Citations (PDF) |
| 752 | CREUTZFELDT-JAKOB DISEASE VIRUS ISOLATIONS FROM THE GERSTMANN-STRÄUSSLER SYNDROMEBrain, 1981, 104, 559-588 | 8.4 | 549 | Citations (PDF) |
| 753 | Golgi and electronmicroscopic studies of spongifom encephalopathy | 1.0 | 53 | Citations (PDF) |
| 754 | Evidence for and against the transmissibility of Alzheimer disease | 1.0 | 177 | Citations (PDF) |
| 755 | 111 THE GERSTMANN-STRʼAUSSLER SYNDROME AND THE VARIOUS FORMS OF AMYLOID PLAQUES WHICH OCCUR IN THE TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES | 1.8 | 7 | Citations (PDF) |
| 756 | Oral Transmission of Kuru, Creutzfeldt-Jakob Disease, and Scrapie to Nonhuman Primates | 3.7 | 145 | Citations (PDF) |
| 757 | Transmissible dementias | 1.0 | 14 | Citations (PDF) |
| 758 | Creutzfeldt‐Jakob disease: Patterns of worldwide occurrence and the significance of familial and sporadic clustering | 6.6 | 651 | Citations (PDF) |
| 759 | PATHOGENESIS OF ENCFPHALOCELE AND ANENCEPHALY: RELATIONSHIP TO HE VENTRICULA SYSTEM AND THE SIGNIFICANCE OF HYDROCEPHALUS | 1.8 | 1 | Citations (PDF) |
| 760 | Pathogenesis of the Arnold-Chiari Malformation: The Significance of Hydrocephalus and Aqueduct Stenosis | 1.8 | 44 | Citations (PDF) |
| 761 | MENKES' KINKY (STEELY) HAIR DISEASE | 0.8 | 10 | Citations (PDF) |
| 762 | PATHOGENESIS OF THE ARNOLD-CHIARI MALFORMATION | 1.8 | 1 | Citations (PDF) |
| 763 | Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease | 0.7 | 51 | Citations (PDF) |
| 764 | Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2020 | 1.0 | 1 | Citations (PDF) |
| 765 | Ammonium hydroxide treatment of Aβ produces an aggregate free solution suitable for biophysical and cell culture characterization | 0.0 | 114 | Citations (PDF) |
| 766 | Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2019 | 1.0 | 3 | Citations (PDF) |
| 767 | Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2021 0, 46, | | 3 | Citations (PDF) |
| 768 | The structural foundations of anti-amyloid-β immunotherapies: Unravelling antibody-antigen interactions in Alzheimer's disease treatment | 2.6 | 9 | Citations (PDF) |
| 769 | Predicting severity of cerebral amyloid angiopathy neuropathology: A modeling approach using NACC and ROSMAP data | 0.5 | 3 | Citations (PDF) |
| 770 | Development and validation of an interpretable clinical scoring model to monitor the progression of preclinical Alzheimer’s disease | 6.5 | 0 | Citations (PDF) |
| 771 | Gut Microbial Composition and Short-Chain Fatty Acid Metabolism in Cognitively Unimpaired Adults Stratified by Amyloid-β Status | 4.2 | 1 | Citations (PDF) |
| 772 | Higher sodium intake is associated with episodic memory decline in cognitively unimpaired older males: A 6-year longitudinal study | 3.4 | 0 | Citations (PDF) |
| 773 | Decreased metallothionein-3 expression in the human spinal cord is a common feature of amyotrophic lateral sclerosis and multiple sclerosis | 3.4 | 1 | Citations (PDF) |
| 774 | Identification of the promoter region of the human P2RX7 gene | 2.4 | 0 | Citations (PDF) |
| 775 | Discovery of lipid biomarkers for idiopathic Parkinson’s disease in red blood cells and plasma | 7.0 | 0 | Citations (PDF) |
